WO2012035055A1 - Nouveaux composés - Google Patents

Nouveaux composés Download PDF

Info

Publication number
WO2012035055A1
WO2012035055A1 PCT/EP2011/065921 EP2011065921W WO2012035055A1 WO 2012035055 A1 WO2012035055 A1 WO 2012035055A1 EP 2011065921 W EP2011065921 W EP 2011065921W WO 2012035055 A1 WO2012035055 A1 WO 2012035055A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridin
amino
thiazolo
methyl
pyridinediamine
Prior art date
Application number
PCT/EP2011/065921
Other languages
English (en)
Inventor
Nicholas Paul Barton
Sebastien Andre Campos
Robin Arthur Carr
John David Harling
Ian Edward David Smith
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of WO2012035055A1 publication Critical patent/WO2012035055A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention is directed to certain novel compounds which are inhibitors of kinase activity, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various disorders. More specifically, the compounds of the invention are inhibitors of the activity or function of Itk (interleukin-2 inducible tyrosine kinase).
  • Itk interleukin-2 inducible tyrosine kinase
  • Compounds which are inhibitors of the activity or function of Itk may be useful in the treatment of disorders such as respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and bronchitis; allergic diseases including allergic rhinitis and atopic dermatitis; autoimmune diseases including rheumatoid arthritis, multiple sclerosis, psoriasis, type I diabetes, T cell mediated hypersensitivities, Guiliain-Barre Syndrome and Hashimoto's thyroiditis; transplant rejection; graft versus host disease; inflammatory disorders including conjunctivitis, contact dermatitis, inflammatory bowel disease and chronic inflammation; HIV; aplastic anemia; and pain including inflammatory pain.
  • respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and bronchitis
  • allergic diseases including allergic rhinitis and atopic dermatitis
  • autoimmune diseases including rheumatoid arthritis, multiple sclerosis, psoriasis,
  • lnterleukin-2 inducible tyrosine kinase is a non-receptor tyrosine kinase of the Tec family, which is also known as Tsk or Emt.
  • Other members of the Tec fami!iy include: Tec, Btk, Txk and Bmx.
  • the Tec family kinases are predominantly expressed in haematopoietic cells, however Bmx and Tec have a wider expression profile.
  • the Tec famiiy kinases share a common domain structure: an amino-terminal pleckstrin homology (PH) domain (absent in Txk), a tec homology domain (containing one or two proline rich regions), followed by Src homology SH3 and SH2 domains, and a carboxy-terminal kinase domain.
  • the PH domain binds to Ptdln(3,4,5)P3, and is responsible for locating the Tec kinase to the plasma membrane, whilst the PRR, SH3 and SH2 domains are involved in protein-interactions important in formation of the signalling complex.
  • Itk expression is restricted to T cells, NK and mast cells. Itk is the predominant Tec family kinase in naive T cells, which also express Txk and Tec. Upon activation via the T cell receptor or interleukin-2 (IL-2), the expression of Itk increases. There is some evidence that Itk is preferentially expressed in Th2 over Th1 ceils, in contrast to Txk which is present at higher levels in Th1 cells (1 ). Itk plays a key role in T cell receptor signalling. Itk is recruited to the plasma membrane through interaction with Ptdlns(3,4,5)P3, which is generated by P!3kinase. Itk forms a complex with several signalling and scaffold proteins including SLP76 and LAT.
  • Itk is transphorphorylated by Lck. Activated Itk phosphoryiates PLCy, leading to the generation of lns(1 ,4,5)P3 (required for calcium flux within the cells) and diacylglycerol (activates members of the protein kinase C family and RAS guanyl-releasing protein. This results in the activation of mitogen-activated protein kinases (including JNK and ERK) and other effectors that regulate gene transcription, leading to the secretion of cytokines (reviewed in ref 2). In addition to the role of itk in PLCy activation and Ca 2+ mobilisation, Itk may also contribute to TCR-induced actin reorganisation, and formation of the immune synapse.
  • actin cytoskeleton may not require kinase activity (3), suggesting the importance of Itk as a scaffold protein.
  • itk may also be activated via the chemokine receptor CXCR4 (4) in T cells, and via the FceRI in mast cells (5).
  • CsA Cyclosporin A
  • CsA inhibited the late phase but not the early phase response (9), suggesting that effects on mast cells are unlikely to play a key role in the beneficial effect seen of CsA.
  • daclizumab an antibody against the anti-IL-2Ra chain (CD25) of activated lymphocytes improved pulmonary function and asthma control in patients with moderate to severe chronic asthma (10), supporting anti-T cell therapy for asthma.
  • Inhibition of Itk represents a potential novel therapy for asthma, by inhibiting T cell cytokine release.
  • the key role for Itk in T cell receptor signalling has been demonstrated using Itk-/- mice and siRNA.
  • In vitro activation of CD4+ cells from Itk knockout mice show reduced levels of Th2 (11) or both Th1 and Th2 (12) cytokines compared to wild type.
  • Naive T cells from Itk knockout mice can differentiate normally into either Th1 or Th2 cells if cultured in vitro under appropriate cytokine conditions, suggesting that Itk is not required for Th2 cell differentiation (12).
  • Itk may be beneficial in a variety of T-ce!l mediated diseases.
  • Itk may play a role in other allergic diseases such as allergic rhinitis and atopic dermatitis.
  • Single nucleotide polymorphisms in Itk have been associated with atopy (18) and seasonal ailergic rhinitis (19).
  • itk mRNA levels in the peripheral blood T cells of atopic dermatitis patient is elevated in T cells from affected patients, compared to healthy controls (20).
  • Such disorders include respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and bronchitis; allergic diseases including allergic rhinitis and atopic dermatitis; autoimmune diseases including rheumatoid arthritis, multiple sclerosis, psoriasis, type I diabetes, T cell mediated hypersensitivities, Guil!ain-Barre Syndrome and Hashimoto's thyroiditis; transplant rejection; graft versus host disease; inflammatory disorders including conjunctivitis, contact dermatitis, inflammatory bowel disease and chronic inflammation; HIV; aplastic anemia; and pain including inflammatory pain.
  • respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and bronchitis
  • allergic diseases including allergic rhinitis and atopic dermatitis
  • autoimmune diseases including rheumatoid arthritis, multiple sclerosis, psoriasis, type I diabetes, T cell mediated hypersensitivities, Guil!a
  • compounds of the invention may show selectivity for itk over other kinases.
  • compounds of the invention may be potent inhibitors of Itk activity.
  • compounds of the invention may be irreversible inhibitors of Itk activity.
  • compounds of the invention may show a fast rate of irreversible inhibition of Itk activity.
  • the invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (i):
  • R 1 to R 3 , X and Y are as defined below, and salts thereof.
  • the compounds are inhibitors of kinase activity, in particular Itk activity, and may have the potential for irreversible inhibition. Compounds which are Itk inhibitors may be useful in the treatment of disorders associated with inappropriate Itk activity, such as asthma. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention is still further directed to methods of inhibiting Itk activity and treatment of disorders associated therewith using a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceuticaliy acceptable salt thereof. The invention is yet further directed towards processes for the preparation of the compounds of the invention.
  • Figure 1 shows an X-ray powder diffraction (XRPD) pattern for A/-[(3S)-1 -acryloyl-3- pyrrolidinyl]-W-[1 ,3]thiazolo[5,4-b]pyridin-2-yl-4-( ⁇ [(1 S)-1 ,2,2- trimethylpropyl]amino ⁇ methyi)-2,6-pyridinediamine difumarate monohydrate.
  • XRPD X-ray powder diffraction
  • the invention is directed to compounds of formula (I)
  • R 1 is hydrogen, -CH 2 OR 4 , -CH 2 NR 5 R 6 , -CH 2 -pheny[ wherein ihe phenyl is optionally substituted by one or two substituents independently selected from C h alky!, C 1-6 alkoxy, nitrile and halo, -CH 2 -6-membered heterocyclyl wherein the 6-membered heterocyclyl optionally contains an oxygen atom and is optionally substituted by one or two substituents independently selected from Ci assign 6 aSkyl and halo, or -CH 2 -5-membered heteroaryl wherein the 5-membered heteroaryl contains one or two nitrogen atoms and is optionally substituted by C 1-6 alkyl;
  • R 2 is -(NH) 2 COCHCH 2> -NR 7 R 8 , -OR 9 or phenyl wherein the phenyl is optionally substituted by -NR 10 R 1 1 ;
  • R 3 is hydrogen, halo, C-
  • R 6 and R 6 are each independently hydrogen or C ⁇ alkyl, or
  • R 5 and R 6 together with the nitrogen atom to which they are attached, are linked to form a
  • 5- or 6-membered heterocyclyl wherein the 6-membered heterocyclyl optionally contains an oxygen atom or a further nitrogen atom and the 5- or 6-membered heterocyclyl is optionally substituted by one or two substituents independently selected from C 1-6 alky! and halo;
  • R 7 is hydrogen or methyl
  • R 8 is -COCHCH 2l - ⁇ CH 2 ) n NR 12 R 13 , C 3 . 6 cycloalkyl substituted by -OS0 2 CH 3 or -NR 14 R 1S , or 4-, 5- or 6-membered heterocyclyl wherein the 4-, 5- or 6-membered heterocyclyl contains a nitrogen atom and is substituted by -R 16 , or
  • R 7 and R 8 together with the nitrogen atom to which they are attached, are linked to form a
  • 6- membered heterocyclyl optionally containing a further nitrogen atom wherein the 6- membered heterocyclyl is substituted by -R 17 or -NR 18 R 19 ;
  • R 9 is 5- or 6-membered heterocyclyl wherein the 5- or 6-membered heterocyclyl contains a nitrogen atom and is substituted by -R 20 ;
  • R 1 1 , R 13 , R 15 , R 6 , R 17 , R 19 and R 20 are each independently -COCR 25 CR 21 R 26 , -COCH 2 halo or -COCH 2 OR 22 ;
  • R 2 is hydrogen, methyl, -CF 3 or -CH 2 NR 23 R 24 ;
  • R 22 is phenyl optionally substituted by halo;
  • R 4 , R 10 , R 2 , R 14 , R 18 , R 23 and R 24 are each independently hydrogen or C h alky!;
  • R 25 is hydrogen, methyl or -CH 2 NR 27 R 28 ;
  • R 26 is hydrogen or methyl; and R , together with the nitrogen atom to which they are attached, are linked to form a 6-membered heterocyclyl optional!y containing an oxygen atom; X and Y are each independently -N- or -CH-; and n is 2, 3 or 4; and salts thereof (hereinafter “compounds of the invention").
  • R 2 is -(NH) 2 COCHCH 2
  • R 8 is - COCHCH 2l
  • R 11 , R 13 , R 5 , R 16 , R 7 , R 19 and R 20 are each independently - COCR 25 CR 21 R 26 , contain carbon-carbon double bonds and may be depicted as shown below wherein "-" denotes the point of attachment:
  • R is hydrogen, ⁇ CH 2 OR 4 , -CH 2 NR 5 R S , -CH 2 -phenyl wherein the phenyl is optionally substituted by one or two substituents independently selected from 6 alkyl, C 6 a!koxy, nitrilo and halo, or -CH 2 -5-membered heteroaryl wherein the 5- membered heteroaryl contains one or two nitrogen atoms and is optionally substituted by C 1-6 alkyl.
  • R 1 is hydrogen, -CH 2 OR 4 , -CH 2 NR 5 R 6 or -CH 2 -5- membered heteroaryl wherein the 5-membered heteroaryl contains one or two nitrogen atoms and is optionally substituted by C h alky!.
  • R 1 is hydrogen, - CH 2 OR 4 , -CH 2 -6-membered heterocyclyl wherein the 6-membered heterocyclyl optionally contains an oxygen atom and is optionally substituted by one or two substituents independently selected from C h alky! and halo, -CH 2 -5-membered heteroaryi wherein the heteroaryi contains one or two nitrogen atoms and is optionally substituted by C h alky!.
  • R 1 is -Ch ⁇ OR 4 , or -CH 2 -6-membered heterocyciyl wherein the 6- membered heterocyciyl optionally contains an oxygen atom and is optionally substituted by one or two substituents independently selected from C 1-6 alkyl and halo.
  • R 1 is -CH 2 OR 4 , in particular wherein R 4 is methyl, !n another embodiment, R 1 is -CH 2 -6-membered heterocyciyl wherein the 6-membered heterocyciyl optionally contains an oxygen atom and is optionally substituted by one or two substituents independently selected from C 1-6 alky! and halo, in particular N-morpho!inyl.
  • R 1 is -CH 2 NR 5 R 6 .
  • R 2 is -NR 7 R 8 , -OR 9 or phenyl wherein the phenyl is optionally substituted by -NR 10 R 11 .
  • R 2 is -NR 7 R 8 .
  • R 2 is -NR 7 R 8 wherein R 7 is hydrogen. In one embodiment, R 2 is -NR 7 R 8 wherein R 8 is -(CH 2 ) n NR 12 R 13 .
  • R 2 is -NR 7 R 8 wherein R 8 is C 3 . 6 cycloalkyl substituted by -NR 14 R 15 , in particular C 6 cycloalkyl substituted by -NR 14 R 15 . In one embodiment, R 2 is -NR 7 R 8 wherein R 8 is 5- or 6-membered heterocyciyl wherein the 5- or 6-membered heterocyciyl contains a nitrogen atom and is substituted by -R 16 .
  • R 2 is -NR 7 R 8 wherein R 8 is 5-membered heterocyciyl wherein the 5- contains a nitrogen atom and is substituted by -R 16 .
  • R 12 or R 14 are each independently hydrogen.
  • R 3 is hydrogen or halo, for example bromo. In another embodiment, R 3 is hydrogen. In a further embodiment, R 3 is C 1-6 alkoxy, for example methoxy. in one embodiment, R 4 is C h alky!, for example methyl.
  • R s and R 6 are each independently hydrogen or C h alky!.
  • R 5 is hydrogen and R e is C 1-6 alkyi, for example 3,3-dimethylbutan-2-yl- (1 ,2,2-trimethylpropyl-).
  • R 5 and R 6 are each independently C-,. 6 alkyl, for example methyl.
  • R 5 and R 6 together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyciyi wherein the 6-membered heterocyciyi optionally contains an oxygen atom or a further nitrogen atom and the 5- or 6- membered heterocyciyi is optionally substituted by one or two substituents independently selected from C -6 alkyl and halo.
  • R 5 and R 6 together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyciyi wherein the 6-membered heterocyciyi optionally contains an oxygen atom or a further nitrogen atom and the 5- or 6-membered heterocyciyi is optionally substituted by one or two substituents independently selected from d-ealkyl.
  • R 5 and R 6 together with the nitrogen atom to which they are attached, are linked to form a 6- membered heterocyciyi wherein the 6-membered heterocyciyi optionally contains an oxygen atom and is optionally substituted by one or two substituents independently selected from C ⁇ alkyl and halo.
  • R 5 and R 6 together with the nitrogen atom to which they are attached, are linked to form a 6-membered heterocyciyi wherein the 6-membered heterocyciyi contains an oxygen atom and is substituted by two substituents independentiy selected from C h alky!, for example methyi.
  • R 7 is hydrogen or methyl
  • R 8 is -COCHCH 2 , -(CH 2 ) n NR 12 R 13 , C 3 . 6 cycloalkyi substituted by -OS0 2 CH 3 or -NR 1 "R 15 , or 5- or 6-membered heterocyciyi wherein the 5- or 6-membered heterocyciyi contains a nitrogen atom and is substituted by -R 16 , or R 7 and R 8 , together with the nitrogen atom to which they are attached, are linked to form a 6-membered heterocyclyl optionally containing a further nitrogen atom wherein the 6- membered heterocyclyl is substituted by -R 7 or -NR 18 R 19 .
  • R 7 is hydrogen.
  • R 8 is 5- or 6-membered heterocyclyl wherein the 5- or 6-membered heterocyclyl contains a nitrogen atom and is substituted by -R 16 . In a further embodiment, R 8 is 5-membered heterocyclyl wherein the 5-membered heterocyclyl contains a nitrogen atom and is substituted by -R 16 .
  • R 9 is 6-membered heterocyclyl wherein the 6-membered heterocyclyl contains a nitrogen atom and is substituted by -R 20 .
  • R 10 is hydrogen.
  • R 1 ⁇ R 13 , R 15 , R 16 , R 17 , R 19 and R 20 are each independently - COCHCHR 21 , -COCH 2 halo or -COCH 2 OR 22 . In one embodiment, R 11 -COCHCHR 21 .
  • R 12 is hydrogen. In a further embodiment, R 12 is Ci. 6 alkyl, for example methyl. In one embodiment, R 3 is -COCHCHR 21 . in one embodiment, R 4 is hydrogen.
  • R 15 is -COCHCHR 21 .
  • R 16 is -COCHCHR 21 , -COCH 2 halo or -COCH 2 OR 2Z . In a further embodiment, R 16 is -COCHCHR 21 .
  • R 7 is -COCHCHR 1 in one embodiment, R 1s is hydrogen. In one embodiment, R 19 is -COCHCHR 21 .
  • R 20 is -COCHCHR 21 .
  • R 21 is hydrogen, -CF 3 or -CH 2 NR 23 R 24 .
  • R 21 is hydrogen.
  • R 22 is phenyl optionally substituted by fluoro.
  • R 23 is C 1-6 aikyl, for example methyl.
  • R 24 is C ⁇ alkyl, for example methyl.
  • R 25 is hydrogen.
  • R 26 is hydrogen
  • R 27 and R 28 together with the nitrogen atom to which they are attached, are linked to form morpho!inyl.
  • X is -N-. In a further embodiment, X is -CH-.
  • Y is -N-. In a further embodiment, Y is -CH-. In one embodiment, n is 2.
  • R 1 is hydrogen, -CH 2 OR 4 , -CH 2 NR 5 R 6 , -CH 2 -phenyl wherein the phenyl is optionally substituted by one or two substituents independently selected from C h alky! , C ⁇ alkoxy, nitrilo and halo, -CH r 6-membered heterocyciyi wherein the 6-membered heterocydyi optionally contains an oxygen atom and is optionally substituted by one or two substituents independently selected from C ⁇ alkyl and halo, or -CH 2 -5-membered heteroary! wherein the 5-membered heteroaryl contains one or two nitrogen atoms and is optionally substituted by Chalky!;
  • R 2 is -(NH) 2 COCHCH 2 , -NR 7 R 8 , -OR 9 or phenyl wherein the phenyl is optionally substituted by -NR 10 R 11 ;
  • R 3 is hydrogen, halo, Chalky!, C -6 alkoxy;
  • R 5 and R 6 are each independently hydrogen or C 1-6 aikyl, or
  • R 5 and R 6 together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocydyi wherein the 6-membered heterocyciyi optionally contains an oxygen atom or a further nitrogen atom and the 5- or 6-membered heterocydyi is optionally substituted by one or two substituents independently selected from C h alky! and halo;
  • R 7 is hydrogen or methyl
  • R 8 is -COCHCH 2] ⁇ (CH 2 ) n NR 1 R 13 , C 3-6 cycloalkyi substituted by -OS0 2 CH 3 or -NR 1 R 5 , or
  • R 7 and R 8 together with the nitrogen atom to which they are attached, are linked to form a
  • 6- membered heterocydyi optionally containing a further nitrogen atom wherein the 6- membered heterocyciyi is substituted by -R 17 or -NR 18 R 19 ;
  • R 9 is 5- or 6-membered heterocyciyi wherein the 5- or 6-membered heterocyciyi contains a nitrogen atom and is substituted by -R 20 ;
  • R 11 , R 13 , R 5 , R 16 , R 17 , R 19 and R 20 are each independently -COCHCHR 21 , -COCH 2 haio or - COCH 2 OR 22 ;
  • R 21 is hydrogen, -CF 3 or -CH 2 NR 23 R 24 ;
  • R 22 is phenyl optionally substituted by halo;
  • R 4 , R 10 , R 12 , R 14 , R 8 , R 23 and R 24 are each independently hydrogen or C h alky!;
  • X and Y are each independently -N- or -CH-; and n is 2, 3 or 4; and salts thereof.
  • the invention is directed to compounds of formula (IB)
  • R 1 is hydrogen, -CH 2 OR 4 , -CH 2 NR 5 R 6 , -CH 2 -phenyl wherein the phenyl is optionally substituted by one or two substituents independently selected from Ci -6 alkyl, C 1-6 alkoxy, nstrilo and halo, -CH 2 -6-membered heterocyclyl wherein the 6-membered heterocyclyl optionally contains an oxygen atom and is optionally substituted by one or two substituents independently selected from C 1-6 alkyl and halo, or -CH 2 -5-membered heteroaryl wherein the 5-membered heteroaryl contains one or two nitrogen atoms and is optionally substituted by C 1-6 alkyl;
  • R 2 is -NR 7 R 8 , -OR 9 or phenyl wherein the phenyl is optionally substituted by -NR 10 R 1 1 ;
  • R 3 is hydrogen, halo, C 1-6 alkyl, C ⁇ alkoxy;
  • R 5 and R 6 together with the nitrogen atom to which they are attached, are linked to form a 6-membered heterocycly! wherein the 6-membered heterocyclyl optionally contains an oxygen atom and is optionaliy substituted by one or two substituents independently selected from C ⁇ alkyl and halo;
  • R 7 is hydrogen or methyl
  • R 8 is -(CH 2 ) n NR 12 R 13 , C 3 . 6 cycloalkyl substituted by -OS0 2 CH 3 or -NR 14 R 15 , or 5- or 6- membered heterocyciyi wherein the 5- or 6-membered heterocyciyi contains a nitrogen atom and is substituted by -R 16 , or
  • R 7 and R 8 together with the nitrogen atom to which they are attached, are linked to form a 6-membered heterocyciyi optionally containing a further nitrogen atom wherein the 6- membered heterocyciyi is substituted by -R 17 or -NR 18 R 19 ;
  • R 9 is 5- or 6-membered heterocycly! wherein the 5- or 6-membered heterocyciyi contains a nitrogen atom and is substituted by -R 20 ;
  • R 1 , R 13 , R 15 , R 16 , R 17 , R 19 and R 20 are each independently -COCHCHR 21 , -COCH 2 halo or - COCH 2 OR 22 ;
  • R 21 is hydrogen, -CF 3 or -CH 2 NR 23 R 24 ;
  • R 22 is phenyl optionally substituted by halo
  • R 4 , R 1Q , R 12 , R 14 , R 18 , R 23 and R 24 are each independently hydrogen or C ⁇ alkyl; X and Y are each independently -N- or -CH-; and n is 2, 3 or 4; and salts thereof.
  • the invention is directed to compounds of formula (IC)
  • R is -CH 2 NR 5 R 6 ;
  • R 2 is -NR 7 R 8 ;
  • R 3 is hydrogen
  • R 5 and R 6 are each independently hydrogen or C 1-6 alkyl, or
  • R 5 and R 6 together with the nitrogen atom to which they are attached, are linked to form a 6-membered heterocyclyl wherein the 6-membered heterocyclyl contains an oxygen atom and is substituted by two substituents independently selected from C 1-e alkyl;
  • R 7 is hydrogen
  • R 8 is 5-membered heterocyclyl wherein the 5-membered heterocyclyl contains a nitrogen atom and is substituted by -R 6 ;
  • R 16 is -COCHCHR 21 ;
  • R 21 is hydrogen;
  • X is -N-; and
  • Y is -CH-; and salts thereof.
  • R 1 is -CH 2 NR 5 R 6 ;
  • R 2 is -NR 7 R e ;
  • R 3 is hydrogen;
  • R 5 and R 6 are each independently hydrogen or C 1-6 alkyl;
  • R 7 is hydrogen;
  • R 8 is 5-membered heterocyciyi wherein the 5-membered heterocyciyi contains a nitrogen atom and is substituted by -R 16 ;
  • R 6 is -COCHCHR 21 ;
  • R 21 is hydrogen;
  • X is -N-
  • Y is -CH-; and salts thereof.
  • Compounds of the invention include the compounds of Examples 1 to 102 and salts thereof.
  • the compound of the invention is selected from the group consisting of:
  • the compound of the invention is selected from the group consisting of:
  • the compound of the invention is selected from the group consisting of:
  • the compound of the invention is selected from the group consisting of:
  • the compound of the invention is selected from:
  • the compound of the invention is:
  • the compound of the invention is:
  • the compound of the invention is:
  • the compound of the invention is:
  • the compound of formula (I) or a salt thereof is selected from the group consisting of:
  • AlkyI refers to a saturated hydrocarbon chain having the specified number of member atoms.
  • C 1-6 alkyl refers to an alky! group having from 1 to 6 member atoms, for example 1 to 4 member atoms.
  • AlkyI groups may be optionally substituted with one or more substituents as defined herein.
  • AlkyI groups may be straight or branched. Representative branched alkyl groups have one, two, or three branches.
  • AlkyI includes methyl, ethyl, propyl (n-propyl and isopropyl), butyl (n-butyl, isobutyl, and t-butyl), pentyl (n-pentyl, isopentyl, and neopentyl), and hexyl.
  • Alkyl groups may also be part of other groups, for example alkoxy.
  • Alkynyl refers to a hydrocarbon chain having the specified number of member atoms and at least one triple bond.
  • C 2 . 6 alkynyl refers to an alkynyl group having from 2 to 6 member atoms, for example 2 to 4 member atoms.
  • Alkynyl groups may be straight or branched.
  • Alkynyl includes ethynyl, 1-propynyl, 1 -butynyl, 2-butynyl, 1- pentynyi, 2-pentynyl, 3-pentynyl, 1-hexynyl, 2-hexynyi and 3-hexynyl.
  • Cycloalkyl refers to a saturated hydrocarbon ring having the specified number of member atoms. Cycloalkyl groups are monocyclic ring systems. For example, C 3 . ecycloalkyl refers to a cycloalkyl group having from 3 to 6 member atoms. Cycloalkyl groups may be optionally substituted with one or more substituents as defined herein. Cycloalkyl includes cyc!opropyl, cyc!obutyl, cyclopentyi, and cyc!ohexyi. In one embodiment, the cycloalkyl groups herein are cyclohexyl.
  • Enantiomerically enriched refers to products whose enantiomeric excess is greater than zero, For example, enantiomerically enriched refers to products whose enantiomeric excess is greater than 50% ee, greater than 75% ee, and greater than 90% ee.
  • Enantiomeric excess or "ee” is the excess of one enantiomer over the other expressed as a percentage. As a result, since both enantiomers are present in equal amounts in a racemic mixture, the enantiomeric excess is zero (0% ee). However, if one enantiomer was enriched such that it constitutes 95% of the product, then the enantiomeric excess would be 90% ee (the amount of the enriched enantiomer, 95%, minus the amount of the other enantiomer, 5%). “Enantiomerically pure” refers to products whose enantiomeric excess is 99% ee or greater. “Half-life” (or “half-lives”) refers to the time required for half of a quantity of a substance to be converted to another chemically distinct species in vitro or in vivo.
  • Halo refers to the halogen radical fluoro, chloro, bromo, or iodo.
  • Heteroaryl refers to an aromatic ring containing from 1 to 3 heteroatoms as member atoms in the ring or rings. Heteroaryl groups containing more than one heteroatom may contain different heteroatoms. Heteroaryl groups may be optionally substituted with one or more substituents if so defined herein.
  • the heteroaryl groups herein are monocyclic ring systems or are fused bicyclic ring systems. Monocyclic heteroaryl rings have 5 or 6 member atoms. Bicyclic heteroaryl rings have 9 or 10 member atoms.
  • Monocyclic heteroaryl includes pyrrolyl, furany!, pyrazolyl, imidazo!yl, oxazolyl, isoxazolyl, oxadiazoiyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl and pyrazinyi.
  • Bicyclic heteroaryl includes indolyl, isoindolyl, indolizinyl, indazolyl, benzimidazoly!, pyrrolopyridinyl, quinoiinyl, isoquinoiinyl, quinoxalinyl, quinazolinyl and naphthridinyi.
  • the heteroaryl groups herein are monocyclic ring systems having 5 member atoms, for example pyrrolyl, pyrazolyl or imidazolyl.
  • Heteroatom refers to a nitrogen, sulphur, or oxygen atom.
  • Heterocyclyl refers to a saturated or unsaturated ring containing 1 or 2 heteroatoms as member atoms in the ring. However, heterocyclyl rings are not aromatic. In certain embodiments, heterocyclyl is saturated. In other embodiments, heterocyclyl is unsaturated but not aromatic. Heterocyclyl groups containing more than one heteroatom may contain different heteroatoms.
  • the heterocyclyl groups herein are monocyclic ring systems having 4, 5 or 6 member atoms. Heterocyclyl groups may be optionally substituted with one or more substituents as defined herein.
  • Heterocyclyl includes azetidinyl, pyrrolidinyl, pyrazo!idinyl, imidazolinyl, oxazoiidiny!, isoxazolidinyl, piperidinyl, piperazinyl and morphoiinyl.
  • the heterocyclyl groups herein are monocyclic ring systems having 5 or 6 member atoms, for example pyrrolidinyl, piperidinyl, piperazinyl, tetrahydro-1 ⁇ 2H)-pyridazinyl and morphoiinyl.
  • Member atoms refers to the atom or atoms that form a chain or ring. Where more than one member atom is present in a chain and within a ring, each member atom is covalently bound to an adjacent member atom in the chain or ring. Atoms that make up a substituent group on a chain or ring are not member atoms in the chain or ring. "Optionally substituted” indicates that a group, such as heteroaryl, may be unsubstituted or substituted with one or more substituents as defined herein. "Substituted” in reference to a group indicates that a hydrogen atom attached to a member atom within a group is replaced.
  • substituted includes the implicit provision that such substitution be in accordance with the permitted valence of the substituted atom and the substituent and that the substitution results in a stable compound (i.e. one that does not spontaneously undergo transformation such as by rearrangement, cyclization, or elimination).
  • a single atom may be substituted with more than one substituent as long as such substitution is in accordance with the permitted valence of the atom.
  • Suitable substituents are defined herein for each substituted or optionally substituted group.
  • “Pharmaceutically acceptable” refers to those compounds, materials, compositions, and dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • the compounds of the invention may exist in solid or liquid form. In the solid state, the compounds of the invention may exist in crystalline or noncrystalline form, or as a mixture thereof.
  • pharmaceutically acceptable solvates may be formed wherein solvent molecules are incorporated into the crystalline lattice during crystallization. Solvates may involve nonaqueous solvents such as ethanol, isopropanoi, DMSO, acetic acid, ethano!amine, and EtOAc, or they may involve water as the solvent that is incorporated into the crystalline lattice.
  • Solvates wherein water is the solvent that is incorporated into the crystalline lattice are typically referred to as "hydrates.” Hydrates include stoichiometric hydrates as well as compositions containing variable amounts of water. The invention includes ail such solvates.
  • the compound of the invention is /V-[ ⁇ 3S)-1-acryloyl-3-pyrrolidinyl]-/V-[1 ,3]thiazolo[5,4-&]pyridin-2-yl-4-( ⁇ [(1 S)- 1 ,2,2-trimethyipropyl]amino ⁇ methy[)-2,6-pyridinediamine difumarate monohydrate.
  • polymorphs may exhibit poiymorphism (i.e. the capacity to occur in different crystalline structures). These different crystalline forms are typically known as "polymorphs".
  • the invention includes all such polymorphs. Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of the crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformabi!ity, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification.
  • polymorphs may be produced, for example, by changing or adjusting the reaction conditions or reagents, used in making the compound. For example, changes in temperature, pressure, or solvent may result in polymorphs. In addition, one polymorph may spontaneously convert to another polymorph under certain conditions.
  • the present invention provides W-[(3S)-1-acryloyl-3-pyrrolidinyl]-W- [1 ,3]thiazoio[5,4-b]pyridin-2-yl-4-( ⁇ [(1 S)-1 ,2,2-trimethylpropyi]amino ⁇ methyl ⁇ -2,6- pyridinediamine or a pharmaceutically acceptable salt thereof in crystalline form.
  • the present invention provides A/-[(3S)-1-acryloyl-3-pyrrolidinyl]- /V-[1 ,3]thiazolo[5,4-/b]pyridin-2-yl-4-( ⁇ [(1 S)-1 ,2,2-trimethyipropyl]amino ⁇ methyi)-2,6- pyridinediamine difumarate monohydrate in crystalline form.
  • the present invention provides a polymorph of /v/-[(3S)-1 ⁇ acryloyl- 3-pyrro!idinyl]- V-[ ,3]thiazolo[5,4-6]pyridin-2-y!-4-( ⁇ [(1 S)-1 ,2,2- trimethylpropyl]amino ⁇ methyl)-2,6-pyridinediamine difumarate monohydrate characterised in that it provides an XRPD pattern comprising peaks (°2 ⁇ ) at about 4.5, about 7.5 and/or about 8.7.
  • the present invention provides a polymorph of W-[(3S)-1-acryloyl- 3-pyrrolidinyl]-W-[1 ,3]thiazolo[5,4-i ) ]pyridm-2-yi-4-( ⁇ t ⁇ 1 S)-1 ,2,2- trimethylpropyl]amino ⁇ methyi)-2,6-pyridinediamine difumarate monohydrate characterised in that it provides an XRPD pattern comprising peaks substantially as set out in Table 1.
  • the present invention provides a polymorph of /V-[(3S)-1 -acryioyi- S-pyrrolidinylj-W-tL ⁇ thiazolors ⁇ -jbjpyhdin ⁇ -yl ⁇ - ⁇ I S)-! ⁇ - trimethy!propyi3amino ⁇ methyi)-2,6-pyridinediarriine difumarate monohydrate characterised in that it provides an XRPD pattern substantialiy in accordance with Figure 1.
  • the invention encompasses polymorphs isolated in pure form or when admixed with other materia!s, for example other polymorphs, or any other materia!.
  • a polymorph in isolated or pure form refers to a sample in which the polymorph is present in an amount of >75%, particularly >90%, more particularly >95% and even more particularly >99% relative to other materials which may be present in the sample.
  • the invention also includes isotopically-labelled compounds, which are identical to the compounds of formula (I) and salts thereof, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number most commonly found in nature.
  • isotopes that can be incorporated into the compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen and fluorine, such as 2 H, 3 H, 11 C, 4 C and 18 F.
  • the compounds according to formuia (!) may contain one or more asymmetric center (also referred to as a chirai center) and may, therefore, exist as individual enantiomers, diastereomers, or other stereoisomer ⁇ forms, or as mixtures thereof.
  • Chirai centers such as chirai carbon atoms, may also be present in a substituent such as an aikyl group.
  • the stereochemistry of a chira! center present in formula (I), or in any chemical structure illustrated herein, is not specified the structure is intended to encompass any stereoisomer and all mixtures thereof.
  • compounds according to formula (I) containing one or more chirai center may be used as racemic mixtures, enantiomerically enriched mixtures, or as enantiomerically pure individual stereoisomers.
  • the invention provides W-II -acryloyl-S-p rrolidinyll-W-tl ⁇ lthiazoloIS ⁇ - b]pyridin-2-yi-4-( ⁇ [1 ,2,2-trimethylpropyl]amino ⁇ methy!)-2,6-pyridinediamine in all stereoisomeric forms, and mixtures thereof.
  • Individual stereoisomers of a compound according to formula (I) which contain one or more asymmetric center may be resolved by methods known to those skilled in the art. For example, such resolution may be carried out (1 ) by formation of diastereoisomeric salts, complexes or other derivatives; (2) by selective reaction with a stereoisomer- specific reagent, for example by enzymatic oxidation or reduction; or (3) by gas-iiquid or liquid chromatography in a chiral enviornment, for example, on a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent.
  • stereoisomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
  • the compounds according to formula (I) may also contain centers of geometric asymmetry. Where the stereochemistry of a center of geometric asymmetry present in formula (I), or in any chemical structure illustrated herein, is not specified, the structure is intended to encompass the trans geometric isomer, the cis geometric isomer, and all mixtures thereof. Likewise, al! tautomeric forms are a!so included in formula (I) whether such tautomers exist in equilibrium or predominately in one form.
  • references herein to compounds of formula (I) and salts thereof covers the compounds of formula (I) as free acids or free bases, or as salts thereof, for example as pharmaceutically acceptable salts thereof.
  • the invention is directed to compounds of formula (!) as the free acid or free base.
  • the invention is directed to compounds of formula (I) and salts thereof.
  • the invention is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof.
  • pharmaceuticaliy acceptable salts of the compounds according to formula (I) may be prepared. Indeed, in certain embodiments of the invention, pharmaceutically acceptable salts of the compounds according to formula (I) may be preferred over the respective free base or free acid because such salts impart greater stability or solubility to the molecule thereby facilitating formulation into a dosage form. Accordingly, the invention is further directed to compounds of formula (I) and pharmaceutically acceptable salts thereof.
  • pharmaceutically acceptable salts refers to salts that retain the desired biological activity of the subject compound and exhibit minimal undesired toxicological effects.
  • salts and solvates having non-pharmaceutically acceptable counter-ions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of other compounds of formula (I) and their pharmaceutically acceptable salts.
  • one embodiment of the invention embraces compounds of formula (I) and salts thereof.
  • compounds according to formula (I) may contain an acidic functional group.
  • Suitable pharmaceuticaiiy-acceptable salts include salts of such acidic functional groups.
  • Representative salts include pharmaceutically acceptable metal salts such as sodium, potassium, lithium, calcium, magnesium, aluminum, and zinc salts; carbonates and bicarbonates of a pharmaceutically acceptable metal cation such as sodium, potassium, lithium, calcium, magnesium, aluminum, and zinc; pharmaceuticaily acceptable organic primary, secondary, and tertiary amines including aliphatic amines, aromatic amines, aliphatic diamines, and hydroxy alkylamines such as methylamine, ethylamine, 2-hydroxyethylamine, diethylamine, TEA, ethyienediamine, ethanolamine, diethanolamine, and cyclohexylamine.
  • compounds according to formula (I) may contain a basic functional group and are therefore capable of forming pharmaceutically acceptable acid addition salts by treatment with a suitable acid.
  • suitable acids include pharmaceutically acceptable inorganic acids and pharmaceutically acceptable organic acids.
  • Representative pharmaceutically acceptable acid addition salts include hydrochloride, hydrobromide, nitrate, methyinitrate, sulfate, bisulfate, sulfamate, phosphate, acetate, hydroxyacetate, phenylacetate, propionate, butyrate, isobutyrate, valerate, maleate, hydroxymaleate, acrylate, fumarate, maiate, tartrate, citrate, salicylate, p- aminosalicyclate, glycollate, lactate, heptanoate, phthalate, oxalate, succinate, benzoate, o-acetoxybenzoate, ch!orobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzo
  • the invention provides a compound which is A/-[(3S)-1-acryloyl-3- pyrrolEdiny]]-/V-[1 ,3]thiazolo[5,4-f)]pyridin-2-yl-4-( ⁇ [(1 S)-1 ,2,2- trimethy!propyl]amino ⁇ methyl)-2,6-pyridinediamine or a pharmaceutically acceptable salt thereof.
  • the invention provides a pharmaceutically acceptable salt of N- [(3S)-1 -acryjoyl-3-pyrrolidinyl3-/V-[1 ,3]thiazolo[5,4-/b3pyridin-2-yl-4-( ⁇ [(1 S)-1 ,2,2 ⁇ trimethylpropyl]amino ⁇ methyl)-2,6-pyridinediamine,
  • the invention provides salts of compounds of formula (!) formed by treatment with fumaric acid, in another embodiment, the invention provides difumarate salts of compounds of formula (I).
  • the invention provides ⁇ /- [ ⁇ 3S)-1-acryloyl-3-pyrrolidinyl]-/v 1 ⁇ [1 ,3]thiazolo[5,4-/b]pyridin-2-y!-4- ⁇ [(1 S)-1 ,2,2- trimethylpropy!]amino ⁇ methyl)-2,6-pyrtdinediamine difumarate.
  • the compounds of the invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out in the following schemes, and can be readily adapted to prepare other compounds of the invention. Specific compounds of the invention are prepared in the Examples section.
  • R 1 is -CH 2 OCH 3
  • R 2 is -NHR 29 NHR 30
  • R 3 is H
  • Y is N
  • R 29 is (CH 2 ) n or C 3 . 6 cycloalkyi
  • R 30 is -COCHCHR 21 , -COCH 2 halo or - COCH 2 OR 22
  • X is N and P is H or an amine protecting group such as Boc).
  • R 1 is H, 2-methyi-1 H-imidazoiyl or N- morpholinylCH 2
  • R 2 is -NHR 29 NHR 30
  • R 3 is H
  • Y is CH or N
  • R 29 is (CH 2 ) n or C 3 .
  • R 30 is -COCHCHR 21 , -COCH 2 halo or -COCH 2 OR 22
  • X is N and P is H or an amine protecting group such as Boc).
  • scheme 2 can be adapted to provide other compounds of formula (I), by replacing the ⁇ , ⁇ -diamine in the penultimate step with for instance (i) an a-hydroxy-to-(N-protected) amino compound (to give a compound of formula i wherein R 2 is OR 9 , or (ii) a phenyl boronic acid optionally substituted by -NR 10 R 11 , in the presence of a palladium catalyst, to give a compound of formula (I) wherein R 2 is phenyl optionally substituted by -NR 10 R 11 , or (iii) an ⁇ , ⁇ -diamine in which either one or both N are incorporated into a 6-membered heterocyclic ring.
  • Scheme 3
  • Compounds of formula (I) wherein R 3 is chloro may be reduced to produce compounds of formula (I) wherein R 3 is hydrogen.
  • Suitable reduction conditions include treatment with ammonium formate under microwave irradiation, in the presence of a suitable catalyst such as palladium on activated carbon, in a suitable solvent such as methanol and at a suitable temperature such as about 130 °C.
  • Compounds of formula (I) wherein R 2 , R 3 and X are as defined above and R 1 is - CH 2 NR 6 R 7 may be prepared from compounds of formula (I) wherein R 1 is -CH 2 OCH 3 by conversion of the methoxy group to the corresponding alcohol by treatment with, for example, boron tribromide in the presence of a suitable solvent such as dichloromethane and at a suitable temperature such as ambient temperature, followed by conversion of the alcohol to the corresponding aldehyde by treatment with, for example, manganese dioxide in the presence of a suitable solvent such as tetrahydrofuran and at a suitable temperature such as about 70°C, followed by reaction with an amine of formula R 6 R 7 NH 2 in the presence of sodium triacetoxyborohydride, a suitable solvent such as dichloromethane and at a suitable temperature such as ambient temperature.
  • Compounds of formula (I) wherein R 2 , R 3 and X are as defined above and R 1 is -CH 2 NH 2 may be prepared from the abovementioned aldehyde by conversion to the corresponding oxime by treatment with, for example, hydroxylamine hydrochloride and sodium acetate in the presence of a suitable sovent such as aqueous ethanol and at a suitable temperature such as ambient temperature, followed by treatment with zinc powder in glacial acetic acid at a suitable temperature such as ambient temperature.
  • a suitable sovent such as aqueous ethanol
  • a suitable temperature such as ambient temperature
  • the invention provides a process for preparing a compound of formula (I) comprising:
  • R 1 , R 3 , X and Y are as defined above and R 2 is NR 7 R 8 wherein R 7 is as defined above and R 8 is -(CH 2 ) n NR 12 R 13 , C 3 . 6 cycloalkyl substituted by -NR 4 R 15 , or 5- or 6- membered heterocyclyl wherein the 5- or 6-membered heterocyclyl contains a nitrogen atom and is substituted by -R 6 , or R 7 and R 8 , together with the nitrogen atom to which they are attached, are linked to form a 6-membered heterocyciyi optionally containing a further nitrogen atom wherein the 6- membered heterocyciyi is substituted by -NR 18 R 19 ;
  • R ⁇ R 3 , X and Y are as defined above and
  • Y 1 is:
  • R 88 is 5- or 6-membered heterocyciyi which contains a nitrogen atom, a 6-membered heterocyciyi containing, and linked through nitrogen, and optionally containing a further nitrogen atom, wherein the 6-membered heterocyciyi is substituted by -NHR 18 ;
  • R 99 is 5- or 6-membered heterocyciyi wherein the 5- or 6-membered heterocyciyi contains a nitrogen atom, or
  • R a is R 11 , R 13 , R 15 , R 16 , R 19 or R 20 are as defined above;
  • a suitable solvent such as /V-methy!-2-pyrrolidone
  • a base such as a tertiary amine such ty/V-diisopropyiethy!amine
  • a suitable temperature such as ambient temperature, or
  • R a is R 11 , R 3 , R 15 , R 16 , R 19 or R 20 are as defined above,
  • the compounds of the invention are inhibitors of kinase activity, in particular Itk activity.
  • Compounds which are Itk inhibitors may be useful in the treatment of disorders wherein the underlying pathology is (at least in part) attributable to inappropriate Itk activity, such as asthma.
  • "Inappropriate Itk activity” refers to any Itk activity that deviates from the normal Itk activity expected in a particular patient. Inappropriate Itk may take the form of, for instance, an abnormal increase in activity, or an aberration in the timing and or control of Itk activity. Such inappropriate activity may result then, for example, from overexpression or mutation of the protein kinase leading to inappropriate or uncontrolled activation. Accordingly, in another aspect the invention is directed to methods of treating such disorders.
  • Such disorders include respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and bronchitis; allergic diseases including allergic rhinitis and atopic dermatitis; autoimmune diseases including rheumatoid arthritis, multiple sclerosis, psoriasis, type I diabetes, T cell mediated hypersensitivities, Guillain-Barre Syndrome and Hashimoto's thyroiditis; transplant rejection; graft versus host disease; inflammatory disorders including conjunctivitis, contact dermatitis, inflammatory bowel disease and chronic inflammation; HIV; aplastic anemia; and pain including inflammatory pain.
  • respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and bronchitis
  • allergic diseases including allergic rhinitis and atopic dermatitis
  • autoimmune diseases including rheumatoid arthritis, multiple sclerosis, psoriasis, type I diabetes, T cell mediated hypersensitivities, Guillain-
  • the disorder mediated by inappropriate Itk activity is a respiratory disease; an allergic disease; an autoimmune disease; transplant rejection; graft versus host disease; an inflammatory disorder; HIV; aplastic anemia; or pain.
  • the disorder mediated by inappropriate Itk activity is asthma, chronic obstructive pulmonary disease (COPD), bronchitis, allergic rhinitis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, psoriasis, type i diabetes, T cell mediated hypersensitivity, Guillain-Barre Syndrome, Hashimoto's thyroiditis, transplant rejection, graft versus host disease, conjunctivitis, contact dermatitis, inflammatory bowel disease, chronic inflammation, HIV, aplastic anemia, or inflammatory pain.
  • COPD chronic obstructive pulmonary disease
  • the disorder mediated by inappropriate Itk activity is asthma.
  • the methods of treatment of the invention comprise administering a safe and effective amount of a compound of formula (I) or a pharmaceuticaliy acceptable sa!t thereof to a patient in need thereof.
  • Individual embodiments of the invention include methods of treating any one of the above-mentioned disorders by administering a safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • treat in reference to a disorder means: (1 ) to ameliorate or prevent the disorder or one or more of the biological manifestations of the disorder, (2) to interfere with (a) one or more points in the biological cascade that leads to or is responsible for the disorder or (b) one or more of the biological manifestations of the disorder, (3) to alleviate one or more of the symptoms or effects associated with the disorder, or (4) to slow the progression of the disorder or one or more of the biological manifestations of the disorder.
  • prevention of a disorder includes prevention of the disorder.
  • prevention is not an absolute term. In medicine, “prevention” is understood to refer to the prophylactic administration of a drug to substantially diminish the likelihood or severity of a disorder or biological manifestation thereof, or to delay the onset of such disorder or biological manifestation thereof.
  • safe and effective amount in reference to a compound of formula (I) or a pharmaceutically acceptable salt thereof or other pharmaceutica!ly-active agent means an amount of the compound sufficient to treat the patient's condition but low enough to avoid serious side effects (at a reasonable benefit/risk ratio) within the scope of sound medical judgment.
  • a safe and effective amount of a compound will vary with the particular compound chosen (e.g.
  • patient refers to a human (including adults and children) or other animal, in one embodiment, “patient” refers to a human.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may be administered by any suitable route of administration, including both systemic administration and topical administration.
  • Systemic administration includes oral administration, parenteral administration, transdermal administration and recta! administration.
  • Parenteral administration refers to routes of administration other than enteral or transdermal, and is typically by injection or infusion.
  • Parenteral administration includes intravenous, intramuscular, and subcutaneous injection or infusion.
  • Topical administration includes application to the skin as well as intraocular, otic, intravaginal, inhaled and intranasal administration.
  • Inhalation refers to administration into the patient's lungs whether inhaled through the mouth or through the nasal passages.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may be administered orally.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may be administered topically.
  • the compounds of formula (! or pharmaceutically acceptable salts thereof may be administered by inhalation.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may be administered intranasally.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. In one embodiment, a dose is administered once per day. in a further embodiment, a dose is administered twice per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound of formula (I) or a pharmaceutically acceptable salt thereof depend on the pharmacokinetic properties of that compound, such as absorption, distribution, and half- life, which can be determined by the skilled artisan.
  • suitable dosing regimens including the duration such regimens are administered, for a compound of formula (I) or a pharmaceutically acceptable salt thereof depend on the disorder being treated, the severity of the disorder being treated, the age and physical condition of the patient being treated, the medical history of the patient to be treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual patient's response to the dosing regimen or over time as individual patient needs change. Typical daily dosages may vary depending upon the particular route of administration chosen.
  • Typical daily dosages for oral administration range from 0.001 mg to 50mg per kg of total body weight, for example from 1 mg to 10mg per kg of total body weight.
  • daily dosages for oral administration may be from Q.5mg to 2g per patient, such as 10mg to 1g per patient.
  • a prodrug of a compound of formula (I) is a functional derivative of the compound which, upon administration to a patient, eventually liberates the compound of formula (I) in vivo.
  • Administration of a compound of formula (I) as a prodrug may enable the skilled artisan to do one or more of the following: (a) modify the onset of the activity of the compound in vivo; (b) modify the duration of action of the compound in vivo; (c) modify the transportation or distribution of the compound in vivo; (d) modify the solubility of the compound in vivo; and (e) overcome a side effect or other difficulty encountered with the compound.
  • Typical functional derivatives used to prepare prodrugs include modifications of the compound that are chemically or enzymaticaliy cleavable in vivo. Such modifications, which include the preparation of phosphates, amides, esters, thioesters, carbonates, and carbamates, are well known to those skilled in the art.
  • the invention thus provides a method of treating a disorder mediated by inappropriate itk activity comprising administering a safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • the invention provides a method of treating a disorder mediated by inappropriate Itk activity comprising administering a safe and effective amount of N-[(ZS)- 1 -acryloyl-S-pyrro!idinylj-W-tl ,33thiazolo[5,4-0]pyridin-2-yi-4-( ⁇ [(1 S)-1 ,2,2- trimethylpropyi]amino ⁇ methyl)-2,6-pyridinediamine or a pharmaceuticaily acceptable salt thereof to a patient in need thereof.
  • the invention provides a method of treating a disorder mediated by inappropriate Itk activity comprising administering a safe and effective amount of /V-[(3S)-1-acryloyl-3-pyrrolidinyl3-W- [1 ,3]thiazolo[5,4-6]pyridin-2-yl-4-( ⁇ [ ⁇ 1 S)- ,2,2-trimethylpropyl]amino ⁇ methyl)-2,6- pyridinediamine to a patient in need thereof.
  • the invention provides a method of treating a disorder mediated by inappropriate Itk activity comprising administering a safe and effective amount of A/-[(3S)-1-acryloyl-3 ⁇ pyrrolidinyl3-/V- [1 ,3jthiazolo[5,4-0]pyridin-2-yl-4-( ⁇ [(1 S)-1 ,2,2-trimethy!propyl]amino ⁇ methyl)-2,6- pyridinediamine difumarate to a patient in need thereof.
  • the disorder mediated by inappropriate Itk activity is selected from the group consisting of respiratory diseases (including asthma, chronic obstructive pulmonary disease (COPD) and bronchitis); allergic diseases (including allergic rhinitis and atopic dermatitis); autoimmune diseases (including rheumatoid arthritis, multiple sclerosis, psoriasis, type I diabetes, T cell mediated hypersensitivities, Guillain-Barre Syndrome and Hashimoto's thyroiditis); transplant rejection; graft versus host disease; inflammatory disorders (including conjunctivitis, contact dermatitis, inflammatory bowel disease and chronic inflammation); HIV; aplastic anemia; and pain including inflammatory pain.
  • respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and bronchitis
  • allergic diseases including allergic rhinitis and atopic dermatitis
  • autoimmune diseases including rheumatoid arthritis, multiple sclerosis, psoriasis, type I diabetes
  • the disorder mediated by inappropriate Itk activity is a respiratory disease.
  • the disorder mediated by inappropriate Itk activity is asthma.
  • the invention provides a method of treating a respiratory disease comprising administering a safe and effective amount of /V-[(3S)-1-acryloyl-3-pyrrolidinylj- W-[1 ,3]thiazolo[5,4-0]pyridin-2-yl-4-( ⁇ [(1 S)-1 ,2,2-trimethylpropyl]amino ⁇ methyl)-2,6- pyridinediamine or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • the invention provides a method of treating a respiratory disease comprising administering a safe and effective amount of A/-[(3S)-1-acryloy!-3-pyrrolidinyl]- ,3]thiazolo[5,4-/f)jpyridin-2-y!-4-( ⁇ [(1 S)-1 ,2,2-trimethylpropyl]amino ⁇ methyl)-2,6- pyridinediamine to a patient in need thereof.
  • the invention provides a method of treating a respiratory disease comprising administering a safe and effective amount of W-[(3S)-1 -acryloy!-3-pyrrolidinyl]-W-[1 ,3]thiazolo[5,4-b]pyridin-2-yl-4- ( ⁇ [(1 S)-1 ,2,2-trimethylpropyl]amino ⁇ methyl)-2,6-pyridtnediamine difumarate to a patient in need thereof.
  • the invention provides a method of treating asthma comprising administering a safe and effective amount of W-[(3S)-1-acry!oyl-3-pyrroiidinyl]-/v ⁇ [1 ,3]thiazolo[5,4-/bjpyridin-2-yl-4-( ⁇ [(1 S)-1 ,2,2-trimethyipropyl]amino ⁇ methyl)-2,6- pyridinediamine or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • the invention provides a method of treating asthma comprising administering a safe and effective amount of W-[ ⁇ 3S)-1-acryloyl-3-pyrrolidinyl]-/V- [1 ,3]thiazo!o[5,4-0]pyridin-2-yl-4-( ⁇ [(1 S)-1 ,2,2-trimethylpropy!]amino ⁇ methyi)-2,6- pyridinediamine to a patient in need thereof.
  • the invention provides a method of treating asthma comprising administering a safe and effective amount of W-[(3S)-1 -acryloyl-3-pyrrolidinyl]-A "-[1 ,3]thiazolo[5,4- >]pyridin-2-yl ⁇ 4-( ⁇ [(1 S)- l ⁇ -tnmethylpropyljaminoJmethy ⁇ -pyridinediarnine difumarate to a patient in need thereof.
  • the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in medical therapy.
  • the invention provides V-f(3S)-1 -acryloyl-3-pyrrolidinyl)-/V-[1 ,3]thia2oSot5,4- 6]pyridin-2-y!-4-( ⁇ [(1 S)-1 ,2,2-trimethylpropyl]amino ⁇ methyl)-2,6-pyridinediamine or a pharmaceutically acceptable salt thereof for use in medical therapy
  • the invention provides A/-[(3S)-1-acryloyl-3-pyrrolidinyl]-A/ , -[1 ,3]thiazolo[5,4- 0]pyridin-2-yl-4- ⁇ [(1 S)-1 ,2,2-trimethylpropyi]amino ⁇ methyl)-2,6-pyhdinediamine for use in medical therapy, in a further embodiment, the invention provides A/-[[(3S)-1 -acryloyl
  • the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of a disorder mediated by inappropriate Itk activity.
  • the invention provides W-[(3S)-1- acryloy!-3-pyrroiidinyl]-W-[1 ,3]th!azolo[5,4-0]pyridin-2-y!-4-( ⁇ [ ⁇ 1 S)-1 ,2,2- trimethylpropyl]amino ⁇ methyl)-2,6-pyridinediamine or a pharmaceutically acceptable salt thereof for use in the treatment of a disorder mediated by inappropriate Itk activity.
  • the invention provides W-[(3S)-1-acryloyi-3-pyrrolidiny!]-A/'- [1 ,3]thiazo!o[5,4-jb]pyridin-2-yl-4-( ⁇ [ ⁇ 1 S)-1 ,2,2-trimethylpropyS]amino ⁇ methy!-2,6- pyridinediamine for use in the treatment of a disorder mediated by inappropriate Itk activity.
  • the invention provides A/-[(3S)-1-acryloyl-3-pyrrolidinyl]- ,33thiazolo[5,4- )]pyridin-2-yl-4-( ⁇ [ ⁇ 1 S)-1 ,2,2-trimethy!propyl]amino ⁇ methyl)-2,6- pyridinediamine difumarate for use in the treatment of a disorder mediated by inappropriate Itk activity.
  • the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a disorder mediated by inappropriate Itk activity.
  • the invention provides the use of A/-[(3S)-1-acryloyl-3-pyrrolidinyl3-/V-[1 ,3]thiazolo[5 > 4- jt>jpyridin-2-yl-4-( ⁇ [(1 S)-1 ,2,2-tnmethylpropyl]amino ⁇ methyl)-2,6-pyhdinediamine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a disorder mediated by inappropriate itk activity.
  • the invention provides the use of A/-[(3S)-1 -acryloyl-3-pyrrolidinyl]-A '-[1 ,3]thiazolo[5,4- jb]pyridin-2-yl-4-( ⁇ [(1 S)-1 ⁇ -tnmethylpropyljaminojmethyl ⁇ .e-pyridinediamine in the manufacture of a medicament for use in the treatment of a disorder mediated by inappropriate Itk activity, in a further embodiment, the invention provides the use of N- [(3S)-1-acry!oyl-3-pyrrolidinyl]-A/ , -[1 ,3]thiazolo[5,4-j ]pyridin-2-yl-4-( ⁇ [(1 S)-1 ,2,2- trimethyipropy!]amino ⁇ methyl)-2,6-pyridinediamine difumarate in the manufacture of a medicament for use in the treatment of a disorder mediated by inappropriate Itk
  • the invention provides a pharmaceutical composition for the treatment or prophylaxis of a disorder mediated by inappropriate Itk activity comprising a compound of formula (I) or a pharmaceuticaliy acceptable salt thereof.
  • the invention provides a pharmaceutical composition for the treatment or prophylaxis of a disorder mediated by inappropriate Itk activity comprising W-[(3S)-1- acryloyl-3-pyrroiidinyl]-/V-[1 ,3]thiazolo[5,4-0]pyridin-2-y!-4-( ⁇ [(1 S)-1 ,2,2- trimethylpropyl]amino ⁇ methyi)-2,6-pyridinediamine or a pharmaceutically acceptable salt thereof.
  • the invention provides a pharmaceutical composition for the treatment or prophylaxis of a disorder mediated by inappropriate Itk activity comprising W-[(3S)-1-acryloyl-3-pyrrolidinyi]-W-[1 ,3]thtazolo[5,4-i)]pyridin-2-yi-4- ⁇ [(1 S)- ,2,2- trimethy!propyl]amino ⁇ methyl)-2,6-pyridinediamine.
  • the invention provides a pharmaceutical composition for the treatment or prophylaxis of a disorder mediated by inappropriate Itk activity comprising W-[(3S)-1 -acryloyl-3-pyrrolidinyl]- v 1 - [1 ,3]thiazolo[5,4-0]pyridin-2-yl-4-( ⁇ [(1 S)-1 ,2,2-trimethylpropyl]amino ⁇ methyl)-2,6- pyridinediamine difumarate.
  • the compounds of formula (I) and pharmaceutically acceptable salts thereof will normally, but not necessarily, be formulated into pharmaceutical compositions prior to administration to a patient.
  • the invention is directed to pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising N- [(SSH-acryioy!-S-pyrrolidiny!l-W-EI ,3]thiazolo[5,4-6]pyridin-2-yl-4-( ⁇ [(1 S)-1 ,2,2- thmethylpropyi3amino ⁇ methyl)-2,6-pyridinediamine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising W-[(3S)-1-acryloyl-3-pyrrolidinyl]-W-[1 ,33thiazolo[5,4-/3]pyridin-2-yl-4-( ⁇ [(1 S)-1 ,2,2- trimethylpropyl]amino ⁇ methyi)-2,6-pyridinediamine and one or more pharmaceutically acceptable excipients.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising W-[ ⁇ 3S)-1-acryloyl-3-pyrrolidinyl]-/V-[1 ,3]thiazolo[5,4-6]pyridin-2-yl-4-( ⁇ [(1 S)-1 ,2,2- trimethylpropyl]amino ⁇ methyl)-2,6-pyridinediamine difumarate and one or more pharmaceutically acceptable excipients.
  • the invention is directed to pharmaceutical compositions for the treatment or prophylaxis of a disorder mediated by inappropriate Itk activity comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical compositions of the invention may be prepared and packaged in bulk form wherein a safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof can be extracted and then given to the patient such as with powders or syrups.
  • the pharmaceutical compositions of the invention may be prepared and packaged in unit dosage form wherein each physically discrete unit contains a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical compositions of the invention typically may contain, for example, from 0.5mg to 1 g, or from 1 mg to 700mg, or from 5mg to 100mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • compositions of the invention typically contain one compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • pharmaceutically acceptable excipient means a pharmaceutically acceptable material, composition or vehicle involved in giving form or consistency to the pharmaceutical composition.
  • Each excipient must be compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of formula (I) or a pharmaceutically acceptable salt thereof when administered to a patient and interactions which would result in pharmaceutical compositions that are not pharmaceutically acceptable are avoided.
  • each excipient must of course be pharmaceutically acceptable eg of sufficiently high purity.
  • dosage forms include those adapted for (1 ) oral administration such as tablets, capsules, caplets, piils, troches, powders, syrups, elixers, suspensions, solutions, emulsions, sachets, and cachets; (2) parenteral administration such as sterile solutions, suspensions, and powders for reconstitution; (3) transdermal administration such as transdermal patches; (4) rectal administration such as suppositories; (5) inhalation such as aerosols, solutions, and dry powders; and (6) topical administration such as creams, ointments, lotions, solutions, pastes, sprays, foams, and gels.
  • Suitable pharmaceutically acceptable excipients will vary depending upon the particular dosage form chosen.
  • suitable pharmaceutically acceptable excipients may be chosen for a particular function that they may serve in the composition.
  • certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the production of uniform dosage forms.
  • Certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the production of stable dosage forms.
  • Certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the carrying or transporting of the compound or compounds of formula (I) or pharmaceutically acceptable salts thereof once administered to the patient from one organ, or portion of the body, to another organ, or portion of the body.
  • Certain pharmaceutically acceptable excipients may be chosen for their ability to enhance patient compliance.
  • Suitable pharmaceuticaliy-acceptabie excipients include the following types of excipients: Diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweetners, flavoring agents, flavor masking agents, coloring agents, anticaking agents, hemectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents.
  • compositions of the invention are prepared using techniques and methods known to those skilled in the art. Some of the methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing Company). Accordingly, in another aspect the invention is directed to process for the preparation of a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically-acceptable excipients which comprises mixing the ingredients.
  • a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof may be prepared by, for example, admixture at ambient temperature and atmospheric pressure.
  • the compounds of formula (! or pharmaceutically acceptable salts thereof will be formulated for oral administration.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof will be formulated for inhaled administration.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof will be formulated for intranasal administration.
  • the invention is directed to a solid oral dosage form such as a tablet or capsule comprising a safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a diluent or filler.
  • Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate.
  • the oral solid dosage form may further comprise a binder. Suitable binders include starch (e.g.
  • the oral solid dosage form may further comprise a disintegrant. Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose.
  • the oral solid dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesuim stearate, calcium stearate, and talc.
  • dosage unit formulations for oral administration can be microencapsulated.
  • the composition can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may also be coupled with soluble polymers as targetabie drug carriers.
  • soluble polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide -phenol, po!yhydroxyethy!aspartamidephenol, or poiyethyleneoxidepolylysine substituted with palmitoyl residues.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caproiactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, poiycyanoacry!ates and cross-linked or amphipathic block copolymers of hydrogels.
  • a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caproiactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, poiycyanoacry!ates and cross-linked or amphipathic block copolymers of hydrogels.
  • the invention is directed to a liquid oral dosage form.
  • Oral liquids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • Syrups can be prepared by dissolving the compound of formula (I) or a pharmaceutically acceptable salt thereof in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle.
  • Suspensions can be formulated by dispersing the compound of formula (I) or a pharmaceutically acceptable salt thereof in a non-toxic vehicle.
  • So!ubilizers and emulsifiers such as ethoxyiated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.
  • the invention is directed to a dosage form adapted for administration to a patient by inhalation.
  • a dosage form adapted for administration to a patient by inhalation.
  • dry powder compositions for delivery to the lung by inhalation typically comprise a compound of formula (i) or a pharmaceutically acceptable salt thereof as a finely divided powder together with one or more pharmaceuticaily-acceptable excipients as finely divided powders.
  • Pharmaceuticaily-acceptable excipients particularly suited for use in dry powders are known to those skilled in the art and include lactose, starch, mannitol, and mono-, di-, and polysaccharides.
  • the finely divided powder may be prepared by, for example, micronisation and milling.
  • the size-reduced (eg micronised) compound can be defined by a D 50 value of about 1 to about 10 microns (for example as measured using laser diffraction).
  • the dry powder may be administered to the patient via a reservoir dry powder inhaler (RDPI) having a reservoir suitable for storing multiple (un-metered doses) of medicament in dry powder form.
  • RDPIs typically include a means for metering each medicament dose from the reservoir to a delivery position.
  • the metering means may comprise a metering cup, which is movable from a first position where the cup may be filled with medicament from the reservoir to a second position where the metered medicament dose is made available to the patient for inhalation.
  • the dry powder may be presented in capsules (e.g. gelatin or plastic), cartridges, or blister packs for use in a multi-dose dry powder inhaler (MDPl).
  • MDPl multi-dose dry powder inhaler
  • MDPIs are inhalers wherein the medicament is comprised within a multi-dose pack containing (or otherwise carrying) multiple defined doses (or parts thereof) of medicament.
  • the dry powder When the dry powder is presented as a blister pack, it comprises multiple blisters for containment of the medicament in dry powder form.
  • the blisters are typically arranged in regular fashion for ease of release of the medicament therefrom.
  • the blisters may be arranged in a generally circular fashion on a disc-form blister pack, or the blisters may be elongate in form, for example comprising a strip or a tape.
  • Each capsule, cartridge, or blister may, for example, contain between 20 ⁇ g-10mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • Aerosols may be formed by suspending or dissolving a compound of formula (I) or a pharmaceutically acceptable salt thereof in a liquified propellant.
  • Suitable propellants include halocarbons, hydrocarbons, and other liquified gases.
  • propellants include: trichlorofluoromethane (propellant 1 1), dichlorofluoromethane (propellant 12), dichlorotetrafluoroethane (propellant 114), tetraf!uoroethane (HFA-134a), 1 ,1 - dif!uoroethane (HFA-152a), difluoromethane (HFA-32), pentafluoroethane (HFA-12), heptaf!uoropropane (HFA-227a), perfluoropropane, perfluorobutane, perfluoropentane, butane, isobutane, and pentane. Aerosols comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof will typically be administered to a patient via a metered dose inhaler (MD!). Such devices are known to those skilled in the art.
  • MD metered dose inhaler
  • the aerosol may contain additional pharmaceutical!y-acceptabie excipients typically used with MDIs such as surfactants, lubricants, cosclerosiss and other excipients to improve the physical stability of the formulation, to improve valve performance, to improve solubility, or to improve taste.
  • additional pharmaceutical!y-acceptabie excipients typically used with MDIs such as surfactants, lubricants, cosclerosiss and other excipients to improve the physical stability of the formulation, to improve valve performance, to improve solubility, or to improve taste.
  • a pharmaceutical aerosol formulation comprising a compound of formula (i) or a pharmaceutically acceptable salt thereof and a fluorocarbon or hydrogen-containing ch!orofluorocarbon as propellant, optionally in combination with a surfactant and/or a cosolvent,
  • a pharmaceutical aerosol formulation wherein the propellant is selected from 1 ,1 ,1 ,2-tetrafluoroethane, 1 ,1 , 1 ,2,3,3,3-heptafluoro-n-propane and mixtures thereof.
  • compositions of the invention may be buffered by the addition of suitable buffering agents.
  • Capsules and cartridges for use in an inhaler or insufflator may be formulated containing a powder mix for inhalation of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a suitable powder base such as lactose or starch.
  • a powder mix for inhalation of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a suitable powder base such as lactose or starch.
  • Each capsule or cartridge may generally contain from 20 ⁇ 9 to 10mg of the compound of formula (I) or pharmaceutically acceptable salt thereof.
  • the compound of formula (I) or pharmaceutically acceptable salt thereof may be presented without excipients such as lactose.
  • the proportion of the active compound of formula (I) or pharmaceutically acceptable salt thereof in the local compositions according to the invention depends on the precise type of formulation to be prepared but will generally be within the range of from 0.001 to 10% by weight. Generally, for most types of preparations, the proportion used will be within the range of from 0.005 to 1 %, for example from 0.01 to 0.5%. However, in powders for inhalation or insufflation the proportion used will normally be within the range of from 0.1 to 5%.
  • Aerosol formulations are preferably arranged so that each metered dose or "puff of aerosol contains from 20 g to 10mg, preferably from 20 ⁇ g to 2000 ⁇ g > more preferably from about 20 ⁇ 9 to 500 ⁇ g of a compound of formula (I).
  • Administration may be once daily or several times daily, for example 2, 3, 4 or 8 times, giving for example 1 , 2 or 3 doses each time.
  • the overall daily dose with an aerosol will be within the range from 100 ⁇ g to 10mg, preferably from 200 ⁇ g to 2000 ⁇ g.
  • the overall daily dose and the metered dose delivered by capsules and cartridges in an inhaler or insufflator will generally be double that delivered with aerosol formulations.
  • the particle size of the particulate (e.g., mtcronised) drug should be such as to permit inhalation of substantially all the drug into the lungs upon administration of the aerosol formulation and will thus be less than 100 microns, desirably less than 20 microns, and in particular in the range of from 1 to 10 microns, such as from 1 to 5 microns, more preferably from 2 to 3 microns.
  • the formulations of the invention may be prepared by dispersal or dissolution of the medicament and a compound of formula (I) or a pharmaceutically acceptable salt thereof in the selected prope!lant in an appropriate container, for example, with the aid of sonication or a high-shear mixer.
  • the process is desirably carried out under controlled humidity conditions.
  • the chemical and physical stability and the pharmaceutical acceptability of the aerosol formulations according to the invention may be determined by techniques well known to those skilled in the art.
  • the chemical stability of the components may be determined by HPLC assay, for example, after prolonged storage of the product.
  • Physical stability data may be gained from other conventional analytical techniques such as, for example, by leak testing, by valve delivery assay (average shot weights per actuation), by dose reproducibility assay (active ingredient per actuation) and spray distribution analysis.
  • the stability of the suspension aerosol formulations according to the invention may be measured by conventional techniques, for example, by measuring flocculation size distribution using a back light scattering instrument or by measuring particle size distribution by cascade impaction or by the "twin impinger” analytical process.
  • twin impinger assay means "Determination of the deposition of the emitted dose in pressurised inhalations using apparatus A” as defined in British Pharmacopaeia 1988, pages A204-207, Appendix XVII C.
  • Such techniques enable the "respirable fraction" of the aerosol formulations to be calculated.
  • MDI means a unit comprising a can, a secured cap covering the can and a formulation metering valve situated in the cap.
  • MDI system includes a suitable channelling device. Suitable channelling devices comprise for example, a valve actuator and a cylindrical or cone-like passage through which medicament may be delivered from the filled canister via the metering valve to the nose or mouth of a patient such as a mouthpiece actuator.
  • MDI canisters generally comprise a container capable of withstanding the vapour pressure of the propellant used such as a plastic or plastic-coated glass bottle or preferably a metal can, for example, aluminium or an alloy thereof which may optionally be anodised, lacquer-coated and/or plastic-coated (for example incorporated herein by reference WO96/32099 wherein part or all of the internal surfaces are coated with one or more fluorocarbon polymers optionally in combination with one or more non-fluorocarbon polymers), which container is closed with a metering valve.
  • the cap may be secured onto the can via ultrasonic welding, screw fitting or crimping.
  • MDIs taught herein may be prepared by methods of the art (e.g.
  • the canister is fitted with a cap assembly, wherein a drug-metering valve is situated in the cap, and said cap is crimped in place.
  • the metallic internal surface of the can is coated with a fluoropolymer, more preferably blended with a non-fluoropolymer.
  • the metailic internal surface of the can is coated with a polymer blend of polytetrafluoroethyiene (PTFE) and polyethersulfone (PES).
  • the whole of the metallic internal surface of the can is coated with a polymer blend of polytetrafluoroethyiene (PTFE) and polyethersulfone (PES).
  • PTFE polytetrafluoroethyiene
  • PES polyethersulfone
  • the metering valves are designed to deliver a metered amount of the formu!ation per actuation and incorporate a gasket to prevent leakage of propellant through the valve.
  • the gasket may comprise any suitable elastomeric materia!
  • valves are commercially available from manufacturers well known in the aerosol industry, for example, from Valois, France (e.g. DF10, DF30, DF60), Bespak pic, UK (e.g. BK300, BK357) and 3M-
  • the DIs may also be used in conjunction with other structures such as, without limitation, overwrap packages for storing and containing the MD!s, including those described in U.S. Patent Nos. 6,1 19,853; 6, 179,1 18; 6,315,112; 6,352,152; 6,390,291 ; and 6,679,374, as well as dose counter units such as, but not limited to, those described in U.S. Patent Nos. 6,360,739 and 6,431 ,168.
  • a metering valve is crimped onto an aluminium can to form an empty canister.
  • the particulate medicament is added to a charge vessel and liquefied propellant together with the optional excipients is pressure filled through the charge vessel into a manufacturing vessel.
  • the drug suspension is mixed before recirculation to a filling machine and an aliquot of the drug suspension is then filled through the metering valve into the canister.
  • a metering valve is crimped onto an aluminium can to form an empty canister.
  • the liquefied propellant together with the optional excipients and the dissolved medicament is pressure filled through the charge vessel into a manufacturing vessel.
  • an aliquot of the liquefied formulation is added to an open canister under conditions which are sufficiently cold to ensure the formulation does not vaporise, and then a metering valve crimped onto the canister.
  • each filled canister is check- weighed, coded with a batch number and packed into a tray for storage before release testing.
  • Suspensions and solutions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof may also be administered to a patient via a nebulizer.
  • the solvent or suspension agent utilized for nebulization may be any pharmaceutically-acceptable liquid such as water, aqueous saline, alcohols or glycols, e.g., ethanol, isopropylalcohol, glycerol, propylene glycol, polyethylene glycol, etc. or mixtures thereof.
  • Saline solutions utilize salts which display little or no pharmacological activity after administration.
  • organic salts such as alkali metal or ammonium halogen salts, e.g., sodium chloride, potassium chloride or organic salts, such as potassium, sodium and ammonium salts or organic acids, e.g., ascorbic acid, citric acid, acetic acid, tartaric acid, etc. may be used for this purpose.
  • alkali metal or ammonium halogen salts e.g., sodium chloride, potassium chloride or organic salts, such as potassium, sodium and ammonium salts or organic acids, e.g., ascorbic acid, citric acid, acetic acid, tartaric acid, etc.
  • organic acids e.g., ascorbic acid, citric acid, acetic acid, tartaric acid, etc.
  • the compound of formula (I) or pharmaceutically acceptable salt thereof may be stabilized by the addition of an inorganic acid, e.g., hydrochloric acid, nitric acid, sulphuric acid and/or phosphoric acid; an organic acid, e.g., ascorbic acid, citric acid, acetic acid, and tartaric acid, etc., a complexing agent such as EDTA or citric acid and salts thereof; or an antioxidant such as antioxidant such as vitamin E or ascorbic acid. These may be used alone or together to stabilize the compound of formula (I) or pharmaceutically acceptable salt thereof.
  • an inorganic acid e.g., hydrochloric acid, nitric acid, sulphuric acid and/or phosphoric acid
  • an organic acid e.g., ascorbic acid, citric acid, acetic acid, and tartaric acid, etc.
  • a complexing agent such as EDTA or citric acid and salts thereof
  • an antioxidant such as antioxidant such as vitamin E or as
  • Preservatives may be added such as benzalkonium chloride or benzoic acid and salts thereof.
  • Surfactant may be added particularly to improve the physical stability of suspensions. These include lecithin, disodium dioctylsulphosuccinate, oleic acid and sorbitan esters.
  • the invention is directed to a dosage form adapted for intranasal administration.
  • Formulations for administration to the nose may include pressurised aerosol formulations and aqueous formulations administered to the nose by pressurised pump. Formulations which are non-pressurised and adapted to be administered topically to the nasal cavity are of particular interest. Suitable formulations contain water as the diluent or carrier for this purpose. Aqueous formulations for administration to the lung or nose may be provided with conventional excipients such as buffering agents, tonicity modifying agents and the like. Aqueous formulations may also be administered to the nose by nebulisation.
  • the compounds of formula (I) or pharmaceuticaily acceptable salts thereof may be formulated as a fluid formulation for delivery from a fluid dispenser, for example a fluid dispenser having a dispensing nozzie or dispensing orifice through which a metered dose of the fluid formulation is dispensed upon the application of a user-applied force to a pump mechanism of the fluid dispenser.
  • a fluid dispenser for example a fluid dispenser having a dispensing nozzie or dispensing orifice through which a metered dose of the fluid formulation is dispensed upon the application of a user-applied force to a pump mechanism of the fluid dispenser.
  • Such fluid dispensers are generally provided with a reservoir of multiple metered doses of the fluid formulation, the doses being dispensable upon sequential pump actuations.
  • the dispensing nozzle or orifice may be configured for insertion into the nostrils of the user for spray dispensing of the fluid formulation into the nasal cavity.
  • a fluid dispenser of the aforementioned type is described and illustrated in WO05/044354, the entire content of which is hereby incorporated herein by reference.
  • the dispenser has a housing which houses a fluid discharge device having a compression pump mounted on a container for containing a fluid formulation.
  • the housing has at least one finger-operable side lever which is movable inwardly with respect to the housing to cam the container upwardly in the housing to cause the pump to compress and pump a metered dose of the formulation out of a pump stem through a nasal nozzle of the housing.
  • the fluid dispenser is of the general type illustrated in Figures 30-40 of WO05/044354.
  • compositions adapted for intranasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered by rapid inhalation through the nasai passage from a container of the powder held close up to the nose.
  • suitable compositions wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops include aqueous or oil solutions of the compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • compositions adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the patient for a prolonged period of time.
  • the active ingredient may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3(6), 318 (1986).
  • compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
  • Ointments, creams and gels may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agent and/or solvents.
  • bases may thus, for example, include water and/or an oil such as liquid paraffin or a vegetable oil such as arachis oil or castor oil, or a solvent such as polyethylene glycol.
  • Thickening agents and gelling agents which may be used according to the nature of the base include soft paraffin, aluminium stearate, cetosteary!
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents or thickening agents.
  • Powders for externa! application may be formed with the aid of any suitable powder base, for example, talc, lactose or starch. Drops may be formulated with an aqueous or nonaqueous base also comprising one or more dispersing agents, solubilising agents, suspending agents or preservatives.
  • Topical preparations may be administered by one or more applications per day to the affected area; over skin areas occlusive dressings may advantageously be used. Continuous or prolonged delivery may be achieved by an adhesive reservoir system.
  • compositions may be applied as a topical ointment or cream.
  • the compound of formula (I) or a pharmaceutically acceptable salt thereof may be employed with either a paraffinic or a water-miscible ointment base.
  • the compound of formula (i) or pharmaceutically acceptable salt thereof may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.
  • compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the compositions may be presented in unit- dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
  • the compound and pharmaceutical formulations according to the invention may be used in combination with or include one or more other therapeutic agents, for example selected from anti-inflammatory agents, anticholinergic agents ⁇ particularly an bA M 2 /Mi receptor antagonist), 3 2 -adrenoreceptor agonists, antiinfective agents, such as antibiotics or antivirals, or antihistamines.
  • other therapeutic agents for example selected from anti-inflammatory agents, anticholinergic agents ⁇ particularly an bA M 2 /Mi receptor antagonist), 3 2 -adrenoreceptor agonists, antiinfective agents, such as antibiotics or antivirals, or antihistamines.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (! or a pharmaceutically acceptable salt thereof together with one or more other therapeutically active agents, for example selected from an anti-inflammatory agent, such as a corticosteroid or an NSAID, an anticholinergic agent, a 2 -adrenoreceptor agonist, an antiinfective agent, such as an antibiotic or an antiviral, or an antihistamine.
  • an anti-inflammatory agent such as a corticosteroid or an NSAID
  • an anticholinergic agent such as a corticosteroid or an NSAID
  • an anticholinergic agent such as a corticosteroid or an NSAID
  • an anticholinergic agent such as a corticosteroid or an NSAID
  • an anticholinergic agent such as a corticosteroid or an NSAID
  • an anticholinergic agent such as a corticosteroid or an NSAID
  • One embodiment of the invention encompasses combinations comprising one or two other therapeutic agents.
  • the other therapeutic ingredient(s) may be used in the form of salts, for example as alkali metal or amine salts or as acid addition salts, or prodrugs, or as esters, for example lower alky! esters, or as solvates, for example hydrates to optimise the activity and/or stability and/or physical characteristics, such as solubility, of the therapeutic ingredient. It will be clear also that, where appropriate, the therapeutic ingredients may be used in optically pure form.
  • the invention encompasses a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a p 2 -adrenoreceptor agonist.
  • 2 -adrenoreceptor agonists examples include salmeterol (which may be a racemate or a single enantiomer such as the R-enantiomer), salbutamol (which may be a racemate or a single enantiomer such as the R-enantiomer), formoterol (which may be a racemate or a single duastereomer such as the R.
  • R-diastereomer salmefamol, fenoterol carmotero!, etanterol, naminterol, clenbuterol, pirbuterol, flerbuterol, reproteroi, bambuterol, indacaterol, terbutaline and salts thereof, for example the xinafoate (1 -hydroxy-2- naphthalenecarboxy!ate) salt of salmeterol, the sulfate salt or free base of salbutamol or the fumarate salt of formoterol.
  • long-acting p 2 -adrenoreceptor agonists for example, compounds which provide effective bronchodilation for about 12 hrs or longer, are preferred.
  • P 2 -adrenoreceptor agonists include those described in WO 02/066422, WO
  • Examples of ⁇ 2 ⁇ re no receptor agonists include:
  • the 3 2 -adrenoreceptor agonist may be in the form of a salt formed with a pharmaceutically acceptable acid selected from sulphuric, hydrochloric, fumaric, hydroxynaphthoic (for example 1- or 3-hydroxy-2-naphthoic), cinnamic, substituted cinnamic, triphenylacetic, sulphamic, sulphanilic, naphthaleneacrylic, benzoic, 4-methoxybenzoic, 2- or 4-hydroxybenzoic, 4-chlorobenzoic and 4-phenylbenzo ' ic acid.
  • a pharmaceutically acceptable acid selected from sulphuric, hydrochloric, fumaric, hydroxynaphthoic (for example 1- or 3-hydroxy-2-naphthoic), cinnamic, substituted cinnamic, triphenylacetic, sulphamic, sulphanilic, naphthaleneacrylic, benzoic
  • Suitable anti-inflammatory agents include corticosteroids.
  • Suitable corticosteroids which may be used in combination with the compounds of formula (I) or pharmaceutically acceptable salts thereof are those oral and inhaled corticosteroids and their pro-drugs which have anti-inflammatory activity. Examples include methyl prednisolone, prednisolone, dexamethasone, fluticasone propionate, 6a,9co-difluoro-11 p-hydroxy-16a- methyl-17a-[(4-methyl-1 ,3-thiazole-5-carbonyl)oxy]-3-oxo-androsta-1 ,4-diene-17 ⁇ - carbothioic acid S-fluoromethy!
  • ester (fluticasone furoate), 6a,9a-difluoro-1 1 -hydroxy-16a-methyl-3-oxo-17a-propionyloxy- androsta-1 ,4-diene-17p-carbothioic acid S-(2-oxo-tetrahydro-furan-3S-yl) ester, 6 ⁇ ,9 ⁇ - difluoro-11 -hydroxy-16a-methyl-3-oxo-17a-(2,2,3,3- tetramethycyciopropylcarbonyl)oxy- androsta-1 ,4-diene-17p-carbothioic acid S-cyanomethyl ester and 6a,9a-difluoro-1 i p- hydroxy-16a-methyl-17a-(1-methycyc!opropylcarbonyl)oxy-3-oxo-androsta-1 ,4-diene-17p- carbothioic acid S-fiuoromethyl ester, beclo
  • Preferred corticosteroids include fluticasone propionate, 6a,9a-difluoro-1 I p-hydroxy-iea-methyl- ⁇ a-t -methyl-l ⁇ -thiazoie-S-carbony oxyj-S-oxo-andro ⁇
  • the corticosteroid is 6 ⁇ ,9 ⁇ - difluoro-17cc-[(2-furanylcarbonyi)oxy]-1 1 p-hydroxy-16 -methyl-3-oxo-androsta-1 ,4-diene- 17p-carbothioic acid S-fiuoromethyl ester.
  • corticosteroids may include those described in WO2002/088167, WO2002/100879, WO2002/12265, WO2002/12266, WO2005/005451 , WO2005/005452, WO2006/072599 and WO2006/072600.
  • Non-steroidal compounds having glucocorticoid agonism that may possess selectivity for transrepression over transactivation and that may be useful in combination therapy include those covered in the following patents: WO03/082827, W098/54159, WO04/005229, WO04/009017, WO04/018429, WO03/104195, WO03/082787, WO03/082280, WO03/059899, WO03/101932, WO02/02565, WO01/16128, WO00/66590, WO03/086294, WO04/026248, WO03/061651 and WO03/08277. Further non-steroidal compounds are covered in: WO2006/000401 , WO2006/000398 and WO2006/015870.
  • anti-inf!ammatory agents examples include non-steroidal anti-inflammatory drugs (NSAID's).
  • NSAID's non-steroidal anti-inflammatory drugs
  • NSAID's examples include sodium cromoglycate, nedocromil sodium, phosphodiesterase (PDE) inhibitors (for example, theophylline, PDE4 inhibitors or mixed PDE3/PDE4 inhibitors), leukotriene antagonists, inhibitors of !eukotriene synthesis (for example montelukast), iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine receptor agonists or antagonists (e.g.
  • adenosine 2a agonists adenosine 2a agonists
  • cytokine antagonists for example chemokine antagonists, such as a CCR3 antagonist
  • inhibitors of cytokine synthesis or 5-lipoxygenase inhibitors.
  • An iNOS (inducible nitric oxide synthase inhibitor) is preferably for oral administration.
  • iNOS inhibitors include those disclosed in WO93/ 3055, WO98/30537, WO02/50021 , W095/34534 and W099/62875.
  • CCR3 inhibitors include those disclosed in WO02/26722.
  • the invention provides the use of the compounds of formula (I) in combination with a phosphodiesterase 4 (PDE4) inhibitor, especially in the case of a formulation adapted for inhalation.
  • PDE4-specific inhibitor useful in this aspect of the invention may be any compound that is known to inhibit the PDE4 enzyme or which is discovered to act as a PDE4 inhibitor, and which are only PDE4 inhibitors, not compounds which inhibit other members of the PDE family, such as PDE3 and PDE5, as well as PDE4.
  • Compounds include c/s-4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1 - carboxylic acid, 2-carbomethoxy-4-cyano-4-(3-cyclopropylmethoxy-4- difluoromethoxyphenyl)cyclohexan-1-one and c/ ' s-[4-cyano-4-(3-cyclopropylmethoxy-4- difluoromethoxyphenyl)cyclohexan-1 -of].
  • anticholinergic agents are those compounds that act as antagonists at the muscarinic receptors, in particular those compounds which are antagonists of the or M 3 receptors, dual antagonists of the ⁇ ,/ ⁇ or M 2 /M 3 , receptors or pan-antagonists of the i/M 2 / 3 receptors.
  • exemplary compounds for administration via inhalation include ipratropium (for example, as the bromide, CAS 22254-24-6, sold under the name Atrovent), oxitropium (for example, as the bromide, CAS 30286-75-0) and tiotropium (for example, as the bromide, CAS 136310-93-5, sold under the name Spiriva).
  • revatropate for example, as the hydrobromide, CAS 262586-79-8) and LAS- 34273 which is disclosed in WO01/041 18.
  • Exemplary compounds for oral administration include pirenzepine (CAS 28797-61-7), darifenacin (CAS 133099-04-4, or CAS 133099- 07-7 for the hydrobromide sold under the name Enablex), oxybutynin (CAS 5633-20-5, sold under the name Ditropan), terodiline (CAS 15793-40-5), tolterodine (CAS 124937-51- 5, or CAS 124937-52-6 for the tartrate, sold under the name Detrol), otiionium (for example, as the bromide, CAS 26095-59-0, sold under the name Spasmomen), trospium chioride (CAS 10405-02-4) and solifenacin (CAS 242478-37-1 , or CAS 242478-38-2 for the succinate
  • anticholinergic agents include compounds which are disclosed in US patent application 60/511009 including, for example:
  • the invention provides a combination comprising a compound of formula (i) or a pharmaceutically acceptable salt thereof together with an H1 antagonist
  • H1 antagonists include, without limitation, amelexanox, astemizole, azatadine, azelastine, acrivastine, brompheniramine, cetirizine, levocetirizine, efietirizine, chlorpheniramine, clemastine, cyc!izine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine, doxylamine, dimethindene, ebastine, epinastine, efietirizine,
  • the invention provides a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an H3 antagonist (and/or inverse agonist).
  • H3 antagonists include, for example, those compounds disclosed in WO2004/035556 and in WO2006/045416.
  • Other histamine receptor antagonists which may be used in combination with the compounds of the present invention include antagonists (and/or inverse agonists) of the H4 receptor, for example, the compounds disclosed in Jablonowski et a/., J. Med. Chem. 46:3957-3960 (2003).
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (!) or a pharmaceutically acceptable salt thereof together with a PDE4 inhibitor.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a 2 -adrenoreceptor agonist.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (!) or a pharmaceutically acceptable salt thereof together with a corticosteroid.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a non-steroidal GR agonist.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an anticholinergic.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (!) or a pharmaceutically acceptable salt thereof together with an antihistamine.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable sa!t thereof together with a PDE4 inhibitor and a agonist.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (! or a pharmaceutically acceptable salt thereof together with an anticholinergic and a PDE-4 inhibitor.
  • the combinations referred to above may conveniently be presented for use in the form of a pharmaceutical composition and thus pharmaceutical compositions comprising a combination as defined above together with a pharmaceutically acceptable diluent or carrier represent a further aspect of the invention.
  • the individual compounds of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
  • the individual compounds will be administered simultaneously in a combined pharmaceutical formulation.
  • Appropriate doses of known therapeutic agents will readily be appreciated by those skilled in the art.
  • the invention thus provides, in a further aspect, a pharmaceutical composition
  • a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with another therapeutically active agent.
  • the invention thus provides, in a further aspect, a pharmaceutical composition
  • a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a PDE4 inhibitor.
  • the invention thus provides, in a further aspect, a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a p 2 -adrenoreceptor agonist.
  • a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a corticosteroid.
  • the invention thus provides, in a further aspect, a pharmaceutical composition
  • a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a non-steroidal GR agonist.
  • the invention thus provides, in a further aspect, a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an anticholinergic.
  • a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceuticaily acceptable salt thereof together with an antihistamine.
  • a pharmaceutical composition comprising a combination of a compound of formula (i) or a pharmaceutically acceptable salt thereof together with a PDE4 inhibitor and a p 2 -adrenoreceptor agonist.
  • the invention thus provides, in a further aspect, a pharmaceutical composition
  • a pharmaceutical composition comprising a combination of a compound of formula (f) or a pharmaceuticaily acceptable salt thereof together with an anticholinergic and a PDE4 inhibitor.
  • A 0.1 % v/v solution of formic acid in water.
  • the UV detection was an averaged signal from wavelength of 210nm to 350nm and mass spectra were recorded on a mass spectrometer using alternate-scan positive and negative mode electrospray ionization.
  • A 10 mM ammonium bicarbonate in water adjusted to pH 10 with ammonia solution.
  • B acetonitrile.
  • the UV detection was an averaged signal from wavelength of 210nm to 350nm and mass spectra were recorded on a mass spectrometer using alternate-scan positive and negative mode electrospray ionization.
  • the UV detection was an averaged signal from wavelength of 210nm to 350nm and mass spectra were recorded on a mass spectrometer using alternate-scan positive and negative mode electrospray ionization.
  • A 10 mM ammonium bicarbonate in water adjusted to pH 10 with ammonia solution.
  • B acetonitrile.
  • the UV detection was an averaged signal from wavelength of 210nm to 350nm and mass spectra were recorded on a mass spectrometer using alternate-scan positive and negative mode electrospray ionization.
  • the UV detection was an averaged signal from waveiength of 210nm to 350nm and spectra were recorded on a mass spectrometer using alternate-scan positive and negative mode electrospray ionization.
  • A 0.1 % v/v solution of formic acid in water.
  • HPLC analysis was conducted on a Sunfire C18 column (150mm x 30mm interna! diameter, 5pm packing diameter) at ambient temperature.
  • A 0.1 % v/v solution of trifluoroacetic acid in water.
  • HPLC analysis was conducted on an XBridge C18 column (150mm x 30mm internal diameter, 5pm packing diameter) at ambient temperature.
  • A 10 mM ammonium bicarbonate in water adjusted to pH 10 with ammonia solution.
  • B acetonitrile.
  • the gradient employed was dependent upon the retention time of the particular compound undergoing purification as recorded in the analytical LCMS, and was as follows: For compounds with an analytical LCMS retention time below 0.6 minutes (LCMS method A) or below 1.5 minutes (LCMS method B) the following gradient was used: Time Flow Rate
  • the UV detection was an averaged signa! from wavelength of 210nm to 350nm and mass spectra were recorded on a mass spectrometer using alternate-scan positive and negative mode electrospray ionization.
  • a microwave vial was charged with A/-[6-[(methyloxy)methyl]-2-(methylsulfonyl)-4- pyrimidinyl][1 ,3]thiazolo[5,4-0]pyridin-2-amine (450 mg, 1.281 mmol) and 1 ,1 - dimethylethyl (2-aminoethyl)carbamate (308 mg, 1.921 mmol) in isopropanol (10 mL). The via! was sealed and was heated in a Biotage Initiator microwave system at 150 °C for 30 minutes. The residue was then evaporated to dryness.
  • a microwave vial was charged with 6-bromo-A/-(2-chioro-4-pyrimidinyl)-1 ,3-benzothiazol- 2-amine (281 mg, 0.823 mmol), 1 ,2-ethanediamine (0.165 mL, 2.468 mmol) and isopropanol (4 mL).
  • the microwave vial was sealed and was heated in a Biotage Initiator microwave to 150 °C for 45 minutes. After cooling, the solid was filtered under reduced pressure to give a yellow solid. The solid was transferred into a microwave vial. 1 ,2- Ethanediamine (0.165 mL, 2.468 mmol) and isopropanol (4 mL) were added.
  • a microwave vial was charged with A/-[6-[(methyloxy)methyl]-2-(methylsulfonyl)-4- pyrimidinyl][1 ,3]thia2olo[5,4-0]pyridin-2-amine (500 mg, 1.423 mmol), 1 ,1-dimethylethyl 4- amtno-1-piperidinecarboxylate (427 mg, 2.134 mmol) and isopropanol (5 mL).
  • the vial was sealed and was heated in a Biotage Initiator microwave at 150 °C for 45 minutes. After cooling, the reaction was filtered under reduced pressure to give a yellow solid.
  • a microwave vial was charged with /V-[6-[(methyioxy)methyl]-2-(methylsulfonyl)-4- pyrimidinyi][1 ,3]thiazolo[5,4-b]pyridin-2-amine (250 mg, 0.71 1 mmol), trans-4- aminocyclohexanol (246 mg, 2.134 mmol) and isopropanol (5 mL).
  • the vial was sealed and was heated in a Biotage Initiator microwave to 150 °C for 45 minutes. After cooling, the reaction was filtered under reduced pressure and the solid was washed with isopropanol. The filtrate was evaporated to dryness.
  • a microwave via! was charged with W-[6-[(methyloxy)methyl]-2-(methyisulfonyl)-4- pyrimidinyl][1 ,3]thiazolo[5,4-j ]pyhdin-2-amine (150 mg, 0.427 mmol), 1 , 1 -dimethylethyl (4- aminobutyl)carbamate (0.245 mL, 1.281 mmol) and isopropanol (4 mL).
  • the vial was sealed and was heated in a Biotage Initiator microwave at 150 °C for 45 minutes. After cooling, the reaction mixture was filtered under reduced pressure and the solid was washed with isopropanol.
  • a microwave vial was charged with A/-[6-[(methyloxy)methyl3-2-(methylsulfonyl)-4- pyrimidinyl3[1 ,3]thiazolo[5,4-d]pyridin-2-amine (150 mg, 0.427 mmol), 1 , 1 -dimethylethyi (3- aminopropyi)carbamate (0,224 mL, 1.281 mmol) and isopropanol (4 mL).
  • the vial was sealed and was heated in a Biotage Initiator microwave to 150 °C for 45 minutes. After cooling, the reaction was filtered under vacuum and the solid was washed with isopropanol to give the title compound (86 mg).
  • a microwave via! was charged with /V-[6-[(methyloxy)methyl]-2-(methylsulfonyl)-4- pyrimidinyl3[1 ,3]thiazolo[5,4-0]pyridin-2-amine (200 mg, 0.569 mmol), rrans-1 ,2- cyclohexanediamine (97 mg, 0.854 mmol) and isopropanol (4 mL).
  • the via! was sealed and was heated in a Biotage Initiator microwave at 150 °C for 30 minutes. The mixture was evaporated to dryness to give a yeliow solid.
  • a microwave vial was charged with A/-[6-[(methyloxy)methyi]-2-(methylsulfony!)-4- pyrimidinyl][1 ,3]thiazolo[5,4-j ]pyridin-2-amine (200 mg, 0.569 mmol), 1 ,3- cyclohexanediamine (97 mg, 0.854 mmol) and isopropanol (4 mL).
  • the vial was sealed and was heated in a Biotage Initiator microwave at 150 °C for 30 minutes. After cooling the reaction was filtered under reduced pressure and the solid was washed with isopropanol. The filtrate was evaporated to dryness to give a yeliow solid.
  • a microwave vial was charged with A/-[6-[(methyloxy)methyl]-2-(methylsu!fonyl)-4- pyrimidinyl][1 ,3]thiazolo[5,4-6]pyridin-2-amine (200 mg, 0.569 mmol), 1 , 1 -dimethylethyl (3S)-3-amino-1-pyrrolidinecarboxylate (159 mg, 0.854 mmol) and isopropanol (4 mL). The vial was sealed and was heated in a Biotage Initiator microwave at 150 °C for 30 minutes.
  • a microwave vial was charged with A/-[6-[(methyloxy)methyl]-2-(methylsulfonyi)-4- pyrimidinyl][1 ,3]thiazolo[5,4-i)]pyridin-2-amine (200 mg, 0.569 mmo!), 1 ,1 -dimethylethyl 1 - piperazinecarboxy!ate (159 mg, 0.854 mmol) and isopropanoi (4 mL).
  • the via! was sealed and was heated in a Biotage Initiator microwave at 150 °C for 30 minutes.
  • a microwave vial was charged with A/-[6-[(methyloxy)methyl]-2-(methylsulfonyl)-4- pyrimtdinyljt Sjthiazo!oiS ⁇ - ⁇ pyridin ⁇ -amine (200 mg, 0.569 mmoi), c/s-1 ,2- cyclohexanediamine (97 mg, 0.854 mmol) and isopropano! (4 mL).
  • the vial was sealed and was heated in a Biotage Initiator microwave at 150 °C for 30 minutes. The mixture was evaporated to dryness to give a ye!low solid.
  • a microwave vial was charged with /V-[6-[(methyloxy)methyl]-2-(methy!sulfonyl)-4- pyrimidinyl][1 ,3]thiazolo[5,4-0]pyridin-2-amine (200 mg, 0.569 mmol), trans- " ,A- cyclohexanediamine (65 mg, 0.569 mmol) and isopropano! (4 mL).
  • the vial was sealed and was heated in a Biotage initiator microwave at 50 °C for 30 minutes. After cooling, the reaction was filtered under reduced pressure and the solid was washed with isopropanol. The filtrate was evaporated to dryness to give a yellow solid.
  • a microwave vial was charged with A/-[6-[(methyloxy)methy!]-2 ⁇ (methylsulfonyi)-4- pyrimidinyl][1 ,3]thiazolo[5,4-i>3pyridin-2-amine (200 mg, 0.569 mmol), 1 , 1-dimethylethyl (3R)-3-amino-1-pyrrolidinecarboxylate (159 mg, 0.854 mmol) and isopropanol (4 mL). The vial was sealed and was heated in a Biotage Initiator microwave at 150 °C for 30 minutes. A further portion of 1 ,1-dimethylethy!
  • a microwave vial was charged with A/-[6-[(methyioxy)methyl]-2-(methylsulfony!)-4- pyrimidinyl][1 ,3]thiazolo[5,4-t>]pyridin-2-amine (200 mg, 0.569 mmol), 1 ,1 -dimethylethyl 4- hydroxy-1-piperidinecarboxylate (229 mg, 1.138 mmol) and sodium hydride (60 % w/w in mineral oil) (68.3 mg, 1.707 mmol) in tetrahydrofuran (3 ml). The vial was sealed and was heated in a Biotage Initiator microwave at 130 °C for 30 minutes.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne certains nouveaux composés. Spécifiquement, l'invention concerne des composés de formule (I) et des sels de ceux-ci. Les composés de l'invention sont des inhibiteurs de l'activité kinase, en particulier de l'activité ItK.
PCT/EP2011/065921 2010-09-17 2011-09-14 Nouveaux composés WO2012035055A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US38392610P 2010-09-17 2010-09-17
US61/383,926 2010-09-17
US201161469168P 2011-03-30 2011-03-30
US61/469,168 2011-03-30
US201161527637P 2011-08-26 2011-08-26
US61/527,637 2011-08-26

Publications (1)

Publication Number Publication Date
WO2012035055A1 true WO2012035055A1 (fr) 2012-03-22

Family

ID=44658739

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/065921 WO2012035055A1 (fr) 2010-09-17 2011-09-14 Nouveaux composés

Country Status (1)

Country Link
WO (1) WO2012035055A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544256A (ja) * 2010-11-19 2013-12-12 リガンド ファーマシューティカルズ インコーポレイテッド 複素環式アミンおよびその使用
CN103804307A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103804290A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800340A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103800338A (zh) * 2012-11-14 2014-05-21 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103804361A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804363A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804291A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804272A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN104628657A (zh) * 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
WO2018122775A1 (fr) * 2016-12-29 2018-07-05 Minoryx Therapeutics S.L. Composés hétéroaryle et leur utilisation
WO2019074275A1 (fr) * 2017-10-11 2019-04-18 주식회사 대웅제약 Nouveau dérivé de 1h-pyrazolopyridine et composition pharmaceutique le contenant
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
CN112638910A (zh) * 2018-08-27 2021-04-09 株式会社大熊制药 新的杂环胺衍生物及包含其的药物组合物
WO2021172922A1 (fr) * 2020-02-26 2021-09-02 주식회사 대웅제약 Procédé de préparation de dérivés d'amine hétérocyclique
RU2796069C1 (ru) * 2020-02-26 2023-05-16 Дэвунг Фармасьютикал Ко., Лтд. Способ получения производных гетероциклического амина

Citations (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013055A1 (fr) 1991-12-24 1993-07-08 The Wellcome Foundation Limited Derives d'amidino et leur utilisation comme inhibiteurs de synthase d'oxyde nitrique
WO1995034534A1 (fr) 1994-06-15 1995-12-21 The Wellcome Foundation Limited Inhibiteurs d'enzymes
US5552438A (en) 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
WO1996032099A1 (fr) 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Inhalateur doseur d'albuterol
WO1998030537A1 (fr) 1997-01-13 1998-07-16 Glaxo Group Limited Inhibiteurs de monoxyde d'azote synthetase
WO1998054159A1 (fr) 1997-05-30 1998-12-03 Schering Aktiengesellschaft Acylanilides non steroidiques heterocycliquement substitues a effet mixte gestagene et androgene
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
WO1999047505A1 (fr) 1998-03-14 1999-09-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Inhibiteurs de pde iii/iv a base de phtalazinones
WO1999062875A1 (fr) 1998-05-30 1999-12-09 Glaxo Group Limited Inhibiteurs de synthase d'oxyde nitrique
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
WO2000066590A2 (fr) 1999-05-04 2000-11-09 Ligand Pharmaceuticals, Inc. Composes modulateurs de recepteur de progesterone tetracycliques et procedes
WO2001004118A2 (fr) 1999-07-14 2001-01-18 Almirall Prodesfarma S.A. Nouveaux derives de quinuclidine et compositions medicales les contenant
WO2001016128A1 (fr) 1999-09-01 2001-03-08 Abbott Laboratories Dibenzopyranes utiles en tant qu'antagonistes du recepteur des glucocorticoides, dans le traitement du diabete
WO2001042193A1 (fr) 1999-12-08 2001-06-14 Theravance, Inc. Agonistes des recepteurs adrenergiques du beta 2
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
WO2002002565A2 (fr) 2000-07-05 2002-01-10 Abbott Laboratories Agents anti-inflammatoires a selectivite glucocortiocoide
WO2002012266A1 (fr) 2000-08-05 2002-02-14 Glaxo Group Limited Derives de 17-beta-carbothioate-17-alpha-arylcarbonyloxyloxy androstane utilises comme anti-inflammatoires
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6360739B1 (en) 1997-06-10 2002-03-26 Smithkline Beecham Corporation Dispenser with doses counter
WO2002026722A1 (fr) 2000-09-29 2002-04-04 Glaxo Group Limited Derives de morpholine-acetamide permettant de traiter les maladies inflammatoires
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
WO2002050021A1 (fr) 2000-12-21 2002-06-27 Glaxo Group Limited Sel phosphate inhibiteur d'oxyde nitrique synthase
WO2002066422A1 (fr) 2001-02-14 2002-08-29 Glaxo Group Limited Derives de phenethanolamine pour le traitement de maladies respiratoires
WO2002070490A1 (fr) 2001-03-08 2002-09-12 Glaxo Group Limited Agonistes de beta-adrenocepteurs
WO2002076933A1 (fr) 2001-03-22 2002-10-03 Glaxo Group Limited Derives formanilides utilises en tant qu'agonistes de l'adrenorecepteur beta2
WO2002088167A1 (fr) 2001-04-30 2002-11-07 Glaxo Group Limited Derives anti-inflammatoires d'androstane 17.beta.-carbothioate ester avec un groupe cyclique en position 17.alpha
WO2002100879A1 (fr) 2001-06-12 2002-12-19 Glaxo Group Limited 17 alpha esters heterocycliques anti-inflammatoires de derives de 17 beta carbothioate androstane
WO2003008277A2 (fr) 2001-07-17 2003-01-30 Riverwood International Corporation Carton d'emballage dote d'un dispositif de distribution ameliore combine a une seule poignee
WO2003008278A1 (fr) 2001-07-17 2003-01-30 Graham Packaging Company, L.P. Recipient en plastique a surfaces actives inversees
WO2003010193A2 (fr) 2001-07-26 2003-02-06 Ecopia Biosciences Inc. Genes et proteines intervenant dans la biosynthese de rosaramicine
WO2003024439A1 (fr) 2001-09-14 2003-03-27 Glaxo Group Limited Derives de phenethanolamine destines au traitement de maladies respiratoires
WO2003042160A1 (fr) 2001-11-13 2003-05-22 Theravance, Inc. Agonistes de recepteur d'aryl aniline beta-2 adrenergique
WO2003059899A1 (fr) 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Mimetiques de glucocorticoides, procedes de fabrication, preparations pharmaceutiques renfermant ces mimetiques et utilisations
WO2003061651A1 (fr) 2002-01-22 2003-07-31 The Regents Of The University Of California Ligands non steroidiens pour le recepteur des corticoides, compositions et utilisations desdits ligands
WO2003072539A1 (fr) 2002-02-28 2003-09-04 Glaxo Group Limited Derives de phenethanolamine pour traiter des maladies respiratoires
WO2003082827A1 (fr) 2002-04-02 2003-10-09 Schering Aktiengesellschaft Derives de quinoleine et d'isoquinoleine, procede de production de ces derives et leur utilisation comme agents anti-inflammatoires
WO2003082280A1 (fr) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Mimetiques de glucocorticoiques, procedes de fabrication, compositions pharmaceutiques, et utilisations correspondants
WO2003086294A2 (fr) 2002-04-11 2003-10-23 Merck & Co., Inc. Derives de 1h-benzo[f]indazol-5-yl utilises en tant que modulateurs selectifs du recepteur glucocorticoide
WO2003091204A1 (fr) 2002-04-25 2003-11-06 Glaxo Group Limited Derives de la phenethanolamine
WO2003104195A1 (fr) 2002-06-06 2003-12-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derives de 4-(aryle ou heteroaryle)-2-butylamine et leur utilisation en tant que ligands de glucocorticoides
WO2004005229A1 (fr) 2002-07-08 2004-01-15 Pfizer Products Inc. Modulateurs du recepteur glucocorticoide
WO2004009017A2 (fr) 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulateurs de recepteurs de glucocorticoides et procede associe
WO2004016578A2 (fr) 2002-07-25 2004-02-26 Glaxo Group Limited Composes medicamenteux
WO2004018429A2 (fr) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Composes mimetiques de glucocorticoide, leurs procedes de fabrication, compositions pharmaceutiques, et leurs utilisations
WO2004022547A1 (fr) 2002-09-06 2004-03-18 Glaxo Group Limited Derives de phenethanolamine, et leur utilisation pour le traitement des maladies respiratoires
WO2004024728A2 (fr) 2002-09-16 2004-03-25 Glaxo Group Limited Composes de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase
WO2004026248A2 (fr) 2002-09-20 2004-04-01 Merck & Co., Inc. Derives d'octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide en tant que modulateurs selectifs de recepteur glucocorticoide
WO2004035556A1 (fr) 2002-10-16 2004-04-29 Glaxo Group Limited Piperazines, (1,4) diazepines, et 2,5-diazabicyclo (2.2.1) heptanes substitues en tant qu'antagonistes de l'histamine h1 et/ou h3 ou antagonistes inverses de l'histamine h3
WO2004037768A2 (fr) 2002-10-28 2004-05-06 Glaxo Group Limited Composes a usage medicinal
WO2004037773A1 (fr) 2002-10-28 2004-05-06 Glaxo Group Limited Derive de phenethanolamine utilise dans le traitement de maladies respiratoires
WO2004037807A2 (fr) 2002-10-22 2004-05-06 Glaxo Group Limited Composes medicinaux
WO2004039766A1 (fr) 2002-11-01 2004-05-13 Glaxo Group Limited Derives de phenylethanolamine pour le traitement de maladies respiratoires
WO2004039762A1 (fr) 2002-11-01 2004-05-13 Glaxo Group Limited Derives de phenethanolamine permettant de traiter des maladies des voies respiratoires
WO2004056823A1 (fr) 2002-12-23 2004-07-08 Glaxo Group Limited Composes de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase
WO2004103998A1 (fr) 2003-05-21 2004-12-02 Glaxo Group Limited Derives de quinoleine utilises en tant qu'inhibiteurs de la phosphodiesterase
WO2005005452A1 (fr) 2003-07-11 2005-01-20 Glaxo Group Limited Compose glucocorticosteroide specifique a activite anti-inflammatoire
WO2005037280A1 (fr) 2003-10-14 2005-04-28 Glaxo Group Limited Antagonistes du recepteur muscarinique de l'acetylcholine
WO2005044354A1 (fr) 2003-11-03 2005-05-19 Glaxo Group Limited Distributeur de fluides
WO2005046586A2 (fr) 2003-11-04 2005-05-26 Glaxo Group Limited Antagonistes du recepteur muscarinique m3 de l'acetylcholine
WO2005058892A1 (fr) 2003-12-19 2005-06-30 Glaxo Group Limited Composes pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de la phosphodiesterase
WO2005090354A1 (fr) 2004-03-16 2005-09-29 Glaxo Group Limited Composes de pyrazolo[3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de pde4
WO2005090348A1 (fr) 2004-03-16 2005-09-29 Glaxo Group Limited Composes de pyrazolo 3,4-b! pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase de type 4 (pde4)
WO2005090353A1 (fr) 2004-03-16 2005-09-29 Glaxo Group Limited COMPOSES DE PYRAZOLO[3,4-b]PYRIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PDE4
WO2005100545A1 (fr) 2004-04-16 2005-10-27 Sanofi-Aventis Deutschland Gmbh Lignees cellulaires doublement transfectees utilisees comme outils de balayage in vitro destines au profilage de composes pharmaceutiques: un modele destine a l'elimination hepatobiliaire
WO2005104745A2 (fr) 2004-04-27 2005-11-10 Glaxo Group Limited Antagonistes des récepteurs muscariniques de l'acétylcholine
WO2006000398A1 (fr) 2004-06-28 2006-01-05 Glaxo Group Limited Derives de 2,3-benzoxazine utilises en tant que modulateurs non steroidiens du recepteur glucocorticoide
WO2006000401A1 (fr) 2004-06-28 2006-01-05 Glaxo Group Limited Oxazines substituees utilisees comme modulateurs du recepteur glucocorticoide
WO2006015870A1 (fr) 2004-08-12 2006-02-16 Glaxo Group Limited Dérivés de tétrahydronaphthalène servant de modulateurs du récepteur des glucocorticoïdes
WO2006045416A1 (fr) 2004-10-19 2006-05-04 F. Hoffmann-La Roche Ag Derives de quinoline
WO2006072599A2 (fr) 2005-01-10 2006-07-13 Glaxo Group Limited Nouveaux composes
WO2006072600A1 (fr) 2005-01-10 2006-07-13 Glaxo Group Limited Androstane 17-alpha-carbonate pour utilisation dans le traitement des problemes inflammatoires et allergiques
WO2007058482A1 (fr) * 2005-11-16 2007-05-24 Lg Life Sciences, Ltd. Inhibiteurs de la proteine kinase
WO2010106016A1 (fr) 2009-03-17 2010-09-23 Glaxo Group Limited Dérivés de pyrimidine utilisés comme inhibiteurs de ltk

Patent Citations (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013055A1 (fr) 1991-12-24 1993-07-08 The Wellcome Foundation Limited Derives d'amidino et leur utilisation comme inhibiteurs de synthase d'oxyde nitrique
US5552438A (en) 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
WO1995034534A1 (fr) 1994-06-15 1995-12-21 The Wellcome Foundation Limited Inhibiteurs d'enzymes
WO1996032099A1 (fr) 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Inhalateur doseur d'albuterol
WO1998030537A1 (fr) 1997-01-13 1998-07-16 Glaxo Group Limited Inhibiteurs de monoxyde d'azote synthetase
WO1998054159A1 (fr) 1997-05-30 1998-12-03 Schering Aktiengesellschaft Acylanilides non steroidiques heterocycliquement substitues a effet mixte gestagene et androgene
US6431168B1 (en) 1997-06-10 2002-08-13 Smithkline Beecham Corporation Dispenser with doses′ counter
US6360739B1 (en) 1997-06-10 2002-03-26 Smithkline Beecham Corporation Dispenser with doses counter
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
WO1999047505A1 (fr) 1998-03-14 1999-09-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Inhibiteurs de pde iii/iv a base de phtalazinones
WO1999062875A1 (fr) 1998-05-30 1999-12-09 Glaxo Group Limited Inhibiteurs de synthase d'oxyde nitrique
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6179118B1 (en) 1998-12-18 2001-01-30 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6679374B2 (en) 1998-12-18 2004-01-20 Smith Kline Beecham Corporation Package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
WO2000066590A2 (fr) 1999-05-04 2000-11-09 Ligand Pharmaceuticals, Inc. Composes modulateurs de recepteur de progesterone tetracycliques et procedes
WO2001004118A2 (fr) 1999-07-14 2001-01-18 Almirall Prodesfarma S.A. Nouveaux derives de quinuclidine et compositions medicales les contenant
WO2001016128A1 (fr) 1999-09-01 2001-03-08 Abbott Laboratories Dibenzopyranes utiles en tant qu'antagonistes du recepteur des glucocorticoides, dans le traitement du diabete
WO2001042193A1 (fr) 1999-12-08 2001-06-14 Theravance, Inc. Agonistes des recepteurs adrenergiques du beta 2
WO2002002565A2 (fr) 2000-07-05 2002-01-10 Abbott Laboratories Agents anti-inflammatoires a selectivite glucocortiocoide
WO2002012265A1 (fr) 2000-08-05 2002-02-14 Glaxo Group Limited 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYLE) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYLE-3-OXO-ANDROST-1,4,-DIENE-17-ACIDE CARBOTHIOIQUE S-FLUOROMETHYLE ESTER UTILISE COMME AGENT ANTI INFLAMMATOIRE
WO2002012266A1 (fr) 2000-08-05 2002-02-14 Glaxo Group Limited Derives de 17-beta-carbothioate-17-alpha-arylcarbonyloxyloxy androstane utilises comme anti-inflammatoires
WO2002026722A1 (fr) 2000-09-29 2002-04-04 Glaxo Group Limited Derives de morpholine-acetamide permettant de traiter les maladies inflammatoires
WO2002050021A1 (fr) 2000-12-21 2002-06-27 Glaxo Group Limited Sel phosphate inhibiteur d'oxyde nitrique synthase
WO2002066422A1 (fr) 2001-02-14 2002-08-29 Glaxo Group Limited Derives de phenethanolamine pour le traitement de maladies respiratoires
WO2002070490A1 (fr) 2001-03-08 2002-09-12 Glaxo Group Limited Agonistes de beta-adrenocepteurs
WO2002076933A1 (fr) 2001-03-22 2002-10-03 Glaxo Group Limited Derives formanilides utilises en tant qu'agonistes de l'adrenorecepteur beta2
WO2002088167A1 (fr) 2001-04-30 2002-11-07 Glaxo Group Limited Derives anti-inflammatoires d'androstane 17.beta.-carbothioate ester avec un groupe cyclique en position 17.alpha
WO2002100879A1 (fr) 2001-06-12 2002-12-19 Glaxo Group Limited 17 alpha esters heterocycliques anti-inflammatoires de derives de 17 beta carbothioate androstane
WO2003008278A1 (fr) 2001-07-17 2003-01-30 Graham Packaging Company, L.P. Recipient en plastique a surfaces actives inversees
WO2003008277A2 (fr) 2001-07-17 2003-01-30 Riverwood International Corporation Carton d'emballage dote d'un dispositif de distribution ameliore combine a une seule poignee
WO2003010193A2 (fr) 2001-07-26 2003-02-06 Ecopia Biosciences Inc. Genes et proteines intervenant dans la biosynthese de rosaramicine
WO2003024439A1 (fr) 2001-09-14 2003-03-27 Glaxo Group Limited Derives de phenethanolamine destines au traitement de maladies respiratoires
WO2003042160A1 (fr) 2001-11-13 2003-05-22 Theravance, Inc. Agonistes de recepteur d'aryl aniline beta-2 adrenergique
WO2003059899A1 (fr) 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Mimetiques de glucocorticoides, procedes de fabrication, preparations pharmaceutiques renfermant ces mimetiques et utilisations
WO2003061651A1 (fr) 2002-01-22 2003-07-31 The Regents Of The University Of California Ligands non steroidiens pour le recepteur des corticoides, compositions et utilisations desdits ligands
WO2003072539A1 (fr) 2002-02-28 2003-09-04 Glaxo Group Limited Derives de phenethanolamine pour traiter des maladies respiratoires
WO2003082280A1 (fr) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Mimetiques de glucocorticoiques, procedes de fabrication, compositions pharmaceutiques, et utilisations correspondants
WO2003082827A1 (fr) 2002-04-02 2003-10-09 Schering Aktiengesellschaft Derives de quinoleine et d'isoquinoleine, procede de production de ces derives et leur utilisation comme agents anti-inflammatoires
WO2003086294A2 (fr) 2002-04-11 2003-10-23 Merck & Co., Inc. Derives de 1h-benzo[f]indazol-5-yl utilises en tant que modulateurs selectifs du recepteur glucocorticoide
WO2003091204A1 (fr) 2002-04-25 2003-11-06 Glaxo Group Limited Derives de la phenethanolamine
WO2003104195A1 (fr) 2002-06-06 2003-12-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derives de 4-(aryle ou heteroaryle)-2-butylamine et leur utilisation en tant que ligands de glucocorticoides
WO2004005229A1 (fr) 2002-07-08 2004-01-15 Pfizer Products Inc. Modulateurs du recepteur glucocorticoide
WO2004009017A2 (fr) 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulateurs de recepteurs de glucocorticoides et procede associe
WO2004016578A2 (fr) 2002-07-25 2004-02-26 Glaxo Group Limited Composes medicamenteux
WO2004018429A2 (fr) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Composes mimetiques de glucocorticoide, leurs procedes de fabrication, compositions pharmaceutiques, et leurs utilisations
WO2004022547A1 (fr) 2002-09-06 2004-03-18 Glaxo Group Limited Derives de phenethanolamine, et leur utilisation pour le traitement des maladies respiratoires
WO2004024728A2 (fr) 2002-09-16 2004-03-25 Glaxo Group Limited Composes de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase
WO2004026248A2 (fr) 2002-09-20 2004-04-01 Merck & Co., Inc. Derives d'octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide en tant que modulateurs selectifs de recepteur glucocorticoide
WO2004035556A1 (fr) 2002-10-16 2004-04-29 Glaxo Group Limited Piperazines, (1,4) diazepines, et 2,5-diazabicyclo (2.2.1) heptanes substitues en tant qu'antagonistes de l'histamine h1 et/ou h3 ou antagonistes inverses de l'histamine h3
WO2004037807A2 (fr) 2002-10-22 2004-05-06 Glaxo Group Limited Composes medicinaux
WO2004037768A2 (fr) 2002-10-28 2004-05-06 Glaxo Group Limited Composes a usage medicinal
WO2004037773A1 (fr) 2002-10-28 2004-05-06 Glaxo Group Limited Derive de phenethanolamine utilise dans le traitement de maladies respiratoires
WO2004039766A1 (fr) 2002-11-01 2004-05-13 Glaxo Group Limited Derives de phenylethanolamine pour le traitement de maladies respiratoires
WO2004039762A1 (fr) 2002-11-01 2004-05-13 Glaxo Group Limited Derives de phenethanolamine permettant de traiter des maladies des voies respiratoires
WO2004056823A1 (fr) 2002-12-23 2004-07-08 Glaxo Group Limited Composes de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase
WO2004103998A1 (fr) 2003-05-21 2004-12-02 Glaxo Group Limited Derives de quinoleine utilises en tant qu'inhibiteurs de la phosphodiesterase
WO2005005452A1 (fr) 2003-07-11 2005-01-20 Glaxo Group Limited Compose glucocorticosteroide specifique a activite anti-inflammatoire
WO2005037280A1 (fr) 2003-10-14 2005-04-28 Glaxo Group Limited Antagonistes du recepteur muscarinique de l'acetylcholine
WO2005044354A1 (fr) 2003-11-03 2005-05-19 Glaxo Group Limited Distributeur de fluides
WO2005046586A2 (fr) 2003-11-04 2005-05-26 Glaxo Group Limited Antagonistes du recepteur muscarinique m3 de l'acetylcholine
WO2005058892A1 (fr) 2003-12-19 2005-06-30 Glaxo Group Limited Composes pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de la phosphodiesterase
WO2005090354A1 (fr) 2004-03-16 2005-09-29 Glaxo Group Limited Composes de pyrazolo[3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de pde4
WO2005090348A1 (fr) 2004-03-16 2005-09-29 Glaxo Group Limited Composes de pyrazolo 3,4-b! pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase de type 4 (pde4)
WO2005090353A1 (fr) 2004-03-16 2005-09-29 Glaxo Group Limited COMPOSES DE PYRAZOLO[3,4-b]PYRIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PDE4
WO2005100545A1 (fr) 2004-04-16 2005-10-27 Sanofi-Aventis Deutschland Gmbh Lignees cellulaires doublement transfectees utilisees comme outils de balayage in vitro destines au profilage de composes pharmaceutiques: un modele destine a l'elimination hepatobiliaire
WO2005104745A2 (fr) 2004-04-27 2005-11-10 Glaxo Group Limited Antagonistes des récepteurs muscariniques de l'acétylcholine
WO2006000398A1 (fr) 2004-06-28 2006-01-05 Glaxo Group Limited Derives de 2,3-benzoxazine utilises en tant que modulateurs non steroidiens du recepteur glucocorticoide
WO2006000401A1 (fr) 2004-06-28 2006-01-05 Glaxo Group Limited Oxazines substituees utilisees comme modulateurs du recepteur glucocorticoide
WO2006015870A1 (fr) 2004-08-12 2006-02-16 Glaxo Group Limited Dérivés de tétrahydronaphthalène servant de modulateurs du récepteur des glucocorticoïdes
WO2006045416A1 (fr) 2004-10-19 2006-05-04 F. Hoffmann-La Roche Ag Derives de quinoline
WO2006072599A2 (fr) 2005-01-10 2006-07-13 Glaxo Group Limited Nouveaux composes
WO2006072600A1 (fr) 2005-01-10 2006-07-13 Glaxo Group Limited Androstane 17-alpha-carbonate pour utilisation dans le traitement des problemes inflammatoires et allergiques
WO2007058482A1 (fr) * 2005-11-16 2007-05-24 Lg Life Sciences, Ltd. Inhibiteurs de la proteine kinase
WO2010106016A1 (fr) 2009-03-17 2010-09-23 Glaxo Group Limited Dérivés de pyrimidine utilisés comme inhibiteurs de ltk

Non-Patent Citations (35)

* Cited by examiner, † Cited by third party
Title
"Comprehensive Heterocyclic Chemistry", vol. II, 1996, PERGAMON PRESS
"Comprehensive Organic Chemistry", 1979, PERGAMON PRESS
"Comprehensive Organic Functional Group Transformations", 1995, ELSEVIER SCIENCE LTD.
"Remin ton's Pharmaceutical Sciences", MACK PUBLISHING COMPANY
"The Handbook of Pharmaceutical Additives", GOWER PUBLISHING LIMITED
"The Handbook of Pharmaceutical Excipients", AMERICAN PHARMACEUTICAL ASSOCIATION AND THE PHARMACEUTICAL PRESS
ALEXANDER ET AL., THE LANCET, vol. 339, 1992, pages 324 - 328
AU-YEUNG ET AL., J IMMUNOL, vol. 176, 2006, pages 3895 - 3899
BENSON ET AL., ALLERGY, vol. 64, 2009, pages 1286 - 1291
BRITISH PHARMACOPAEIA, 1988, pages A204 - 207
BUSSE ET AL., AM J RESPIR CRIT CARE MED, vol. 178, 2008, pages 1002 - 1008
FERRARA ET AL., J ALLERGY CLIN IMMUNOL, vol. 117, 2006, pages 780 - 786
FISCHER, J BIOL CHEM, vol. 279, no. 28, 2004, pages 29816 - 29820
FORSSELL ET AL., AM J RESPIR CELL MOL BIOL, vol. 32, 2005, pages 511 - 520
FOWELL ET AL., IMMUNITY, vol. 11, 1999, pages 399 - 409
GRASIS ET AL., J IMMUNOL, vol. 170, 2003, pages 3971 - 3976
GRAVES ET AL., J ALLERGY CLIN IMMUNOL, vol. 116, 2005, pages 650 - 656
HOFGEN, N. ET AL., 15TH EFMC INT SYMP MED CHEM, 6 September 1998 (1998-09-06), pages 98
HUANG ET AL: "Discovery of 2-amino-6-carboxamidobenzothiazoles as potent Lck inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 18, no. 7, 6 March 2008 (2008-03-06), pages 2324 - 2328, XP022574955, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2008.02.079 *
IRENA CALETA ET AL: "Novel Cyano- and Amidinobenzothiazole Derivatives: Synthesis, Antitumor Evaluation, and X-ray and Quantitative Structure-Activity Relationship (QSAR) Analysis", JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, no. 6, 26 March 2009 (2009-03-26), pages 1744 - 1756, XP055014067, ISSN: 0022-2623, DOI: 10.1021/jm801566q *
JABLONOWSKI ET AL., J. MED. CHEM., vol. 46, 2003, pages 3957 - 3960
JAGABANDHU DAS ET AL: "Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56lck inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 13, no. 15, 4 August 2003 (2003-08-04), pages 2587 - 2590, XP002646268, ISSN: 0960-894X, [retrieved on 20030619], DOI: 10.1016/S0960-894X(03)00511-0 *
KAWAKAMI ET AL., J IMMUNOL, vol. 155, 1995, pages 3556 - 3562
LANDELLS, L.J. ET AL., EUR RESP J, vol. 12, no. 28, 18 September 1998 (1998-09-18), pages 2393
LIN ET AL., BIOCHEMISTRY, vol. 43, no. 34, 2004, pages 11056 - 11062
LOCK ET AL., AM J RESPIR CRIT CARE MED, vol. 153, 1996, pages 509 - 514
MATSUMOTO, INT ARCH ALLERGY IMMUNOL, vol. 129, 2002, pages 327 - 340
MILLER ET AL., IMMUNITY, vol. 21, 2004, pages 67 - 80
MUELLER, AUGUST, J IMMUNOL, vol. 170, 2003, pages 5056 - 5063
NIZANKOWSKA ET AL., EUR RESPIR J, vol. 8, 1995, pages 1091 - 1099
PHARMACEUTICAL RESEARCH, vol. 3, no. 6, 1986, pages 318
R.C. LAROCK: "Comprehensive Organic Transformations", 1989, VCH PUBLISHERS INC.
SCHAEFFER ET AL., NATURE IMMUNOL, vol. 2, no. 12, 2001, pages 1183 - 1188
SCHWARTZBERG ET AL., NATURE REVIEWS IMMUNOL, vol. 5, 2005, pages 284 - 295
SIHRA ET AL., THORAX, vol. 52, 1997, pages 447 - 452

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10030034B2 (en) 2010-11-19 2018-07-24 Ligand Pharmaceuticals Incorporated Heterocycle amines and uses thereof
US11186593B2 (en) 2010-11-19 2021-11-30 Ligand Pharmaceuticals Incorporated Heterocycle amines and uses thereof
JP2013544256A (ja) * 2010-11-19 2013-12-12 リガンド ファーマシューティカルズ インコーポレイテッド 複素環式アミンおよびその使用
US10604533B2 (en) 2010-11-19 2020-03-31 Ligand Pharmaceuticals Incorporated Heterocycle amines and uses thereof
US11773110B2 (en) 2010-11-19 2023-10-03 Ligand Pharmaceuticals Incorporated Heterocycle amines and uses thereof
CN103804307A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103804361A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804291A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804290A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800340A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804272A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804363A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103800338A (zh) * 2012-11-14 2014-05-21 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN104628657A (zh) * 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
US11858938B2 (en) 2015-03-16 2024-01-02 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
WO2018122775A1 (fr) * 2016-12-29 2018-07-05 Minoryx Therapeutics S.L. Composés hétéroaryle et leur utilisation
US11739072B2 (en) 2016-12-29 2023-08-29 Minoryx Therapeutics S.L. Heteroaryl compounds and their use
JP2020504122A (ja) * 2016-12-29 2020-02-06 ミノリックス セラピューティクス エセ．エレ． ヘテロアリール化合物およびその使用
JP7171057B2 (ja) 2016-12-29 2022-11-15 ミノリックス セラピューティクス エセ．エレ． ヘテロアリール化合物およびその使用
US11174242B2 (en) 2016-12-29 2021-11-16 Minoryx Therapeutics S.L. Heteroaryl compounds and their use
CN111212833A (zh) * 2017-10-11 2020-05-29 株式会社大熊制药 新型苯基吡啶衍生物及包含其的药物组合物
US11149019B2 (en) 2017-10-11 2021-10-19 Daewoong Pharmaceutical Co., Ltd. Phenylpyridine derivative and pharmaceutical composition comprising the same
CN111212833B (zh) * 2017-10-11 2022-09-06 株式会社大熊制药 苯基吡啶衍生物及包含其的药物组合物
AU2018349293B2 (en) * 2017-10-11 2020-10-08 Daewoong Pharmaceutical Co., Ltd. Novel phenylpyridine derivative and pharmaceutical composition comprising the same
KR20190040773A (ko) * 2017-10-11 2019-04-19 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
WO2019074275A1 (fr) * 2017-10-11 2019-04-18 주식회사 대웅제약 Nouveau dérivé de 1h-pyrazolopyridine et composition pharmaceutique le contenant
CN112638910A (zh) * 2018-08-27 2021-04-09 株式会社大熊制药 新的杂环胺衍生物及包含其的药物组合物
CN112638910B (zh) * 2018-08-27 2024-06-11 株式会社大熊制药 新的杂环胺衍生物及包含其的药物组合物
WO2021172922A1 (fr) * 2020-02-26 2021-09-02 주식회사 대웅제약 Procédé de préparation de dérivés d'amine hétérocyclique
CN115151537A (zh) * 2020-02-26 2022-10-04 株式会社大熊制药 制备杂环胺衍生物的方法
RU2796069C1 (ru) * 2020-02-26 2023-05-16 Дэвунг Фармасьютикал Ко., Лтд. Способ получения производных гетероциклического амина
EP4112617A4 (fr) * 2020-02-26 2024-03-13 Daewoong Pharmaceutical Co., Ltd. Procédé de préparation de dérivés d'amine hétérocyclique

Similar Documents

Publication Publication Date Title
US10946025B2 (en) Compounds
WO2012035055A1 (fr) Nouveaux composés
US20120058984A1 (en) Pyrimidine derivatives used as itk inhibitors
EP2507231A1 (fr) Dérivés d'indazole comme inhibiteurs des pi3-kinases
WO2011067365A1 (fr) Dérivés de benzpyrazole comme inhibiteurs des pi3 kinases
US10793559B2 (en) Chemical compounds
WO2011110575A1 (fr) Dérivés de 2-[2-(benzo- ou pyrido-)thiazolylamino]-6- aminopyridine, utiles dans le traitement de maladies respiratoires, allergiques ou inflammatoires
EP3612536B1 (fr) Dérivés de oxepinopyrazole en tant qu'inhibiteurs de l'activité de la kinase pi3
WO2019020657A1 (fr) Composés de pyridine-3-sulfonamide utilisés en tant qu'inhibiteurs de pi3-kinase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11758442

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11758442

Country of ref document: EP

Kind code of ref document: A1